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Objectives: 
The objectives of this dissertation were to: (1) describe and compare the incidence and 
odds of gastrointestinal and intracranial bleeding in veterans age 50 to 89 who were prescribed 
warfarin, direct oral anticoagulants, or no oral anticoagulants; (2) identify risk factors for 
gastrointestinal and intracranial bleeding among older veterans prescribed oral anticoagulants, 
and to calculate the relative risk of bleeding over time through time-to-event analysis; and (3) 
develop and compare models to predict risk of gastrointestinal and intracranial bleeding among 
veterans age 50 to 89 who were prescribed warfarin or direct oral anticoagulants using traditional 
and machine learning methods. These objectives were designed to assist healthcare organizations 
meet goals for the reduction of anticoagulant-related adverse drug events.  
Methods: 
The three studies in this dissertation were carried out using a retrospective cohort design 
and data from the Veterans Health Administration, American Community Survey, and National 
Center for Health Statistics. In Study 1, incidence and odds of gastrointestinal and intracranial 
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bleeding were calculated using the full cohort of subjects and compared across three groups: 
those with no prescription for oral anticoagulants, those with a prescription for a direct oral 
anticoagulant, and those with a prescription for warfarin. In Study 2, time-to-event analysis for 
gastrointestinal or intracranial bleeding was conducted and independent risk factors identified for 
subjects with a prescription for an oral anticoagulant (warfarin or direct oral anticoagulant). In 
Study 3, predictive models were developed using traditional algorithms and machine learning 
tools to predict risk of gastrointestinal or intracranial bleeding for subjects with a prescription for 
oral anticoagulants. 
The primary independent variable for all three studies was the subject’s prescription 
category: no oral anticoagulant, warfarin, or direct oral anticoagulant. The primary dependent 
variable was a dichotomous variable indicating the presence of an ICD-9 or ICD-10 code for 
gastrointestinal or intracranial bleeding in the electronic health record. Diagnosis codes for 
bleeding were associated with any type of clinical encounter, including inpatient admissions, 
outpatient visits, or emergency room visits. Each subject’s index date was the date of the first 
outpatient clinical encounter from October 1, 2010 to September 30, 2011 for the first study, and 
the first OAC prescription date on or after October 1, 2010 for the second and third studies. The 
cohort was drawn from patients with at least two primary care visits between October 1, 2010 
and September 30, 2011 at a VISN-2 facility and assigned a primary care provider. Subjects 
included in the study did not have a prescription for an oral anticoagulant in the six months prior 
to index date. 
Results: 
 Study 1 found that veterans who were not prescribed oral anticoagulants experienced an 
average of 9 to 10 times the number of gastrointestinal bleeding events, and an average of 7 to 8 
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times the intracranial bleeding events as would be expected in the general population. Using 
either a no blackout or 5-day blackout period approach, this study found lower incidence rates 
per 100 person-years for gastrointestinal and intracranial bleeding among veterans prescribed 
oral anticoagulants than previous studies on both veterans and non-veterans. This study also 
found lower odds of bleeding among veterans prescribed an oral anticoagulant than previous 
studies; this was the case regardless of approach. Finally, an important finding of Study 1 was 
the significant difference in incidence between the no blackout period and the 5-day blackout 
period approaches. 
 Study 2 found that as the time from oral anticoagulant prescription increased, the 
proportion of veterans age 50 and older who did not experience a gastrointestinal or intracranial 
bleeding event after being prescribed warfarin was similar to those prescribed direct oral 
anticoagulants. Findings were similar veterans with a diagnosis of atrial fibrillation. This finding 
was reversed in subjects age 75 or older, but all of these differences were small and not 
statistically significant. This study also found that prescriptions for antidepressants or statins 
were the strongest risk factors for gastrointestinal or intracranial bleeding for all subjects, while 
history of bleeding was the strongest risk factor for subjects with a diagnosis of atrial fibrillation 
and for subjects age 75 or older. 
 Study 3 found that a logistic regression model using the traditional ORBIT algorithm 
performed the best out of 12 models developed to predict gastrointestinal or intracranial bleeding 
risk. A logistic regression model with a subset of five variables performed second best. Two 
machine learning algorithms also performed fairly well in predicting bleeding risk: a lasso model 





 The greatest gains in preventing adverse drug events associated with oral anticoagulants 
will likely be realized with increased sharing and use of electronic health data, and the ability to 
discover predictive models that perform well on a variety of evaluation measures. Findings of the 
three studies presented here were mixed in terms of being consistent with previous research, and 
additional research is necessary to understand these differences. Reducing the occurrence of 
gastrointestinal and intracranial bleeding following prescription of oral anticoagulants is an on-
going challenge, and while the studies presented in this dissertation shed some light on older 
veterans and risk of gastrointestinal and intracranial bleeding, there are no easy answers to 
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1.1 Adverse Drug Events are Common and Costly 
An Adverse Drug Event (ADE) is any unintended, undesirable, or harmful reaction 
resulting from the use of a medication, including its intended use, errors in administration, 
inappropriate prescribing, intentional or accidental poisoning, or abuse.1 According to the U.S. 
Department of Health and Human Services (HHS), ADEs lead to approximately 1.3 million 
emergency room and 3.5 million outpatient clinic visits, and 350,000 hospital admissions every 
year.2 In addition, ADEs account for more than 60% of hospital post-discharge complications, 
approximately half of which are preventable.2 The cost of ADEs is estimated at $76 billion per 
year,3 with those occurring in the hospital costing $4.2 billion per year.2 The three medication 
classes most commonly associated with ADEs are Anticoagulants, Diabetes Agents, and 
Opioids.4 Oral Anticoagulants (OACs) are a subclass of anticoagulants, and are most commonly 
prescribed for use outside of the hospital.4 Many ADEs associated with OACs can be prevented, 
yet they remain a significant problem.4 
1.1.a Adverse Drug Events and Veterans 
Adverse drug events among veterans is a problem that has been documented in the 
research literature since at least 1971,5 however only a few studies on ADEs have been published 
since then that examined veterans as a population, despite an increasing focus on patient safety 
within the Veterans Health Administration (VHA) – the healthcare delivery arm of the U.S. 
Department of Veterans Affairs (VA). The 1971 study found a lower ADE incidence rate at the 
single VA facility where the study was conducted compared to non-VA hospitals.5 A more 
recent study using data from across the VA system found similar rates of ADEs compared to 
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non-VA hospitals.6 Another study found higher rates of ADEs in a VA hospital, but attributed 
the higher number to the availability and quantity of electronic health data within the VA, which 
allowed for identification of ADEs that might not have been identified at non-VA facilities 
without an electronic health record system.7 A 2016 report by the Rand Corporation found 
quality of care in VA facilities is as good as or better than private facilities,8 but the ability of VA 
facilities to continue to make improvements in patient safety and quality are hindered by a lack 
of recent studies of OAC-related ADEs in veterans. This gap gave rise to the desire to focus on 
veterans as a population of interest for this dissertation. 
1.2 Bleeding is the Most Common Adverse Drug Event Associated with Oral 
Anticoagulant Use 
Bleeding is the most common ADE associated with OAC use,9–12 with gastrointestinal 
bleeding being the most common type, and intracranial bleeding the most likely to be 
permanently disabling or fatal.13,14 Oral anticoagulants are often prescribed to patients with a 
diagnosis of atrial fibrillation, deep vein thrombosis, pulmonary embolism, mechanical heart 
valves, or following acute myocardial infarction to help prevent the formation of blood clots.12 
Gastrointestinal and intracranial bleeding are the two outcomes of interest in the three studies 
presented in Chapters 2, 3, and 4 of this dissertation.  
1.3 Warfarin is the Most Commonly Used Oral Anticoagulant 
Warfarin has been the most commonly used OAC for more than 60 years and is effective, 
but increases the risk of bleeding.15 Each year approximately 15-20% of those taking warfarin 
experience a bleeding event.16,17 Bleeding for those taking warfarin is approximately five times 
higher than for those not taking OACs.18 In addition, bleeding associated with warfarin is higher 
in the first month of use than when users are more experienced.17,19,20 From 2010 to 2014, 20 to 
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30 million prescriptions for warfarin were written every year.21 The cost for a 30-day supply of 
warfarin is approximately $10.22 Previous studies found incidence rates for gastrointestinal 
bleeding of 3.71 per 100 person-years, and for intracranial bleeding of 0.67 per 100 person-years 
among subjects prescribed warfarin.23 Another study found an incidence rate of 0.78 per 100 
person-years for intracranial bleeding among veterans age 75 or older prescribed warfarin.24 
Taking warfarin along with aspirin raises the risk of bleeding 2.5 times; taking warfarin and non-
aspirin antiplatelet medications raises the risk of bleeding by 3 times.15 Patients taking warfarin 
require frequent blood monitoring using the International Normalized Ratio (INR) test, with a 
result considered to be in a therapeutic range if it is between 2 and 3 for most indications.25 
Warfarin also has many food and drug interactions.25  
1.4 Direct Oral Anticoagulants Were First Approved in 2010 
Direct Oral anticoagulants (DOACs), first approved by the U.S. Food and Drug 
Administration (FDA) in 2010,26 generally have a shorter acting time than warfarin, do not 
require regular blood testing, and have fewer food and drug interactions.25 However, previous 
studies have found that DOACs have a longer acting time in older adults.27 The three most 
commonly prescribed DOACs are dabigatran, rivaroxaban, and apixaban. 
Since the introduction of DOACs the number of annual warfarin prescriptions has fallen. 
The number of annual prescriptions written for these three DOACs has increased every year 
since 2010, even though they cost 30 to 40 times as much as warfarin. Dabigatran was the first 
DOAC approved by the FDA on October 19, 2010.26 Since being approved there have been 
approximately two to three million prescriptions for dabigatran every year.21 The cost for a 30-
day supply of dabigatran is approximately $359.22 Rivaroxaban was approved by the FDA on 
July 1, 2011.26 Since being approved there have been approximately two to three million 
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prescriptions for rivaroxaban every year.21 The cost for a 30-day supply of rivaroxaban is 
approximately $397.22 Apixaban was approved by the FDA on December 28, 2012.26 There were 
approximately 1.3 million prescriptions for apixaban in 2014,21 the only year for which data were 
available. The cost for a 30-day supply of apixaban is approximately $406.22 Figure 1.1 shows 
prescription trends for warfarin and these three DOACs from 2010 to 2014. 
A recent retrospective cohort study found the risk of gastrointestinal bleeding was lower 
in patients prescribed DOACs versus those prescribed warfarin, though in patients older than 75 
this finding was reversed, and gastrointestinal bleeding risk was higher for those using DOACs 
than warfarin.27 Two recent meta-analyses had contradictory findings: one found the risk of 
gastrointestinal bleeding was increased for those taking DOACs versus warfarin when the 
indication was acute myocardial infarction or prevention of venous thrombosis;9 while the other 
found lower rates of major and fatal bleeding in patients taking DOACs.28 Studies published 
using clinical trials data show that half of the clinical trials for DOACs excluded patients who 
had risk factors or conditions predisposing them to bleeding – such as concomitant use of aspirin 
or non-aspirin antiplatelet medications – making the patient populations studied less like those 
seen by providers in usual clinical practice.9,27,29 Warfarin and the three DOACs discussed above 
(dabigatran, rivaroxaban, and apixaban) are the exposures of interest for the three studies 
presented in Chapters 2, 3, and 4.  
1.5 Bleeding Risk Algorithms Were Developed for Atrial Fibrillation Patients Taking Oral 
Anticoagulants 
Older adults with a diagnosis of atrial fibrillation are those most likely to be taking 
OACs, and this patient population has been well studied. Several bleeding risk algorithms were 
developed over the last two decades based on studies of cohorts of atrial fibrillation patients. 
5 
 
Four of the more recent and comparatively studied bleeding risk algorithms and the variables 
they include are listed in Table 1.1. These four algorithms – HAS-BLED, ATRIA, QBLEED, 
and ORBIT – were used as comparators in the study presented in Chapter 4. 
The Area Under the Curve (AUC) is a statistical measure used to assess how well an 
algorithm predicts whether subjects will experience a specified outcome.30 The higher the AUC 
the better the algorithm is at predicting the outcome. Benchmark ranges for AUC used in 
previous research categorized AUC as: poor if < 0.6, fair if 0.6 to 0.69, good if 0.7 to 0.79, very 
good if 0.8 to 0.89, and excellent if 0.9 to 1.0.31 
A study comparing HAS-BLED to other bleeding risk algorithms found HAS-BLED had 
a higher AUC (ranging from 0.60-0.66) than the four other algorithms to which it was 
compared.32 The original study describing HAS-BLED as a convenient and effective predictor of 
bleeding risk found an AUC range of 0.72-0.91.24 Both of these studies focused on patients with 
atrial fibrillation participating in studies related to interventions for their diagnosis (rather than 
OAC use), so that may account for the varying results. A recent study comparing a newer 
bleeding risk algorithm, ORBIT, to the HAS-BLED and ATRIA algorithms found ORBIT had 
an AUC of 0.67, compared to 0.64 for HAS-BLED and 0.66 for ATRIA.33 This study used a 
completely different population for validating the risk models, and found the AUCs decreased by 
approximately 0.05 for each of the three models when applied to the new datasets.33 The HAS-
BLED algorithm is recommended as the preferred method for determining bleeding risk 
according to the European Society of cardiology34 and the American College of Cardiology.35 
The ability to use existing algorithms to assign risk can save healthcare organizations many 
hours of work in developing their own. 
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The studies that generated the algorithms in Table 1.1 used clinical and administrative 
data, with limited demographic, lifestyle, and socioeconomic variables. The QBLEED algorithm, 
based on studies done in the U.K., found Townsend score – a population measure of relative 
material deprivation – was a predictor for bleeding risk.34 None of these studies used machine 
learning in the development of algorithms. Machine learning and Townsend score are discussed 
in more detail in sections 1.7 Machine Learning, and 1.9.d. Methods Overview. 
1.6 Policies and Guidelines for Reducing Oral Anticoagulant-Related Bleeding 
Reducing harm to patients taking anticoagulants has been a Joint Commission Patient 
Safety Goal (PSG) for hospitals, ambulatory care, and long-term care since 2008.36 Performance 
elements associated with this goal include baseline INR testing, following evidence-based 
guidelines, and having and following written facility policies related to anticoagulant 
management.37 A randomized controlled trial from Canada published five years prior to the PSG 
found patients taking OACs managed by anticoagulation clinics had an INR Therapeutic Time in 
Range (TTIR) of 82% versus 76% for those patients managed by family medicine doctors.38 
Despite these and similar findings in other studies, many patients taking anticoagulants are not 
managed in specialized clinics.39  
In July 2015 the VHA published a new policy on anticoagulation therapy management.40 
This policy requires providers with patients taking OACs to perform periodic risk assessments of 
these patients, including assessing bleeding risk and calculating TTIR for patients prescribed 
warfarin.40 Computer-based tools are currently being implemented that will allow VHA 
pharmacists to automatically calculate a patient’s TTIR, but a method for assessing risk has yet 
to be developed or implemented. 
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The National Action Plan for Adverse Drug Event Prevention is a set of goals published 
by HHS in 2014 that aim to reduce the number of ADEs experienced by patients in all healthcare 
settings.4 Anticoagulants are included as a class of medications targeted in the plan.4 The Federal 
Interagency Steering Committee and Workgroups for ADEs published targets and measures for 
the goals in September 2017.2 The target for anticoagulants is a 10% reduction in inpatient and 
outpatient ADEs by 2020.41 Although these goals and targets for reduction are not considered 
law, there is an incentive for healthcare organizations to meet them. Measurement of 
anticoagulant-related ADEs that occur in hospitals will be included in the Hospital-Acquired 
Condition Reduction Program, which beginning October 1, 2017, called for hospitals with a 
Hospital-Acquired Condition score above a certain threshold to be penalized with a 1% Medicare 
payment reduction.42 There is no similar incentive for outpatient, home health, or long-term care, 
even though most OAC prescriptions are for patients who are not hospitalized.38,39 The Hospital 
Acquired Condition policy does not apply to VA hospitals. 
Reaching the goals set forth by The Joint Commission, VHA, and National Action Plan 
will require increased sharing, use, and integration of electronic health data – not just from 
electronic health records, but also from insurance claims, pharmacy benefit managers, public 
health departments, and regional health information exchanges. The amount of available 
healthcare data is growing at a rate of 48% per year, faster than the 40% per year in other sectors 
of the economy.43 In order to use this growing volume of data in meaningful ways, the use of 
automated tools and processes will be crucial. 
1.7 Machine Learning is a Tool for Adverse Drug Event Detection and Prediction  
Machine learning is a subfield of computer science concerned with the development and 
implementation of computerized algorithms that improve with experience,44 or automatically 
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improve by analyzing data.45,46 Machine learning algorithms, or tools, improve by “learning” 
from the data they are given to analyze. This learning process is categorized as supervised or 
unsupervised.45,46 In supervised machine learning the data contain both inputs (characteristics, 
features, risk factors) and outputs (outcomes of interest),45,46 so the machine learning algorithm is 
“trained” in looking for the specified outcome. In practice this is done by using part of the data 
for training and part for validation.47 The machine learning algorithm is first run using the 
training dataset, exposing the outcome of interest to the algorithm, so for each record in the data 
the algorithm knows whether or not the outcome was present. Next the algorithm is run on the 
remaining portion of the data, or a completely new dataset, with the outcome masked from the 
algorithm. The algorithm makes a prediction about each subject – was the outcome present? The 
machine learning algorithm results can then be compared to actual outcomes to determine how 
well the algorithm performed. Unsupervised machine learning algorithms do not contain an 
outcome of interest, so the algorithm relies solely on inputs in order to determine associations in 
the data.45,46 Unsupervised machine learning is best for describing the relationships between data, 
while supervised learning is better for making predictions.48 The math underlying machine 
learning algorithms includes linear and logistic regression, and Bayesian probabilistic models45–
47 – methods familiar to health researchers. Some nonlinear machine learning algorithms use 
hidden computational layers that can contain sigmoidal, planar, or other non-probabilistic 
functions to make predictions;47 these are sometimes referred to as “black-box” algorithms.45 An 
advantage of using machine learning tools based on familiar statistical methods is the ability to 
interpret the results.45,47  Machine learning algorithms can process larger datasets and more 
combinations of data than can be handled using traditional statistical methods,49 including 
datasets too large for or with processing requirements beyond the capability of a single 
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computer. Machine learning could enable the analysis of more and different types of data to 
detect bleeding among those prescribed OACs, and to predict who is at greatest risk of bleeding.  
1.8 The Method Used to Detect Adverse Drug Events has a Significant Impact on Findings       
The traditional method for collecting data about ADEs has been through voluntary 
reporting. Hospitals and healthcare systems collect data on ADEs reported by providers and 
staff. The FDA hosts two web-based reporting portals for consumers, healthcare providers, 
manufacturers, researchers and research participants to report ADEs.50,51 Medical diagnosis 
codes – the International Classification of Diseases 9th and 10th Revisions (ICD-9 and ICD-10) 
include codes specifically for diagnosing a condition related to an ADE, but they are 
underutilized.4 Research shows voluntary reporting of ADEs results in underestimation of the 
true count of events. A study comparing the incidence of inpatient ADEs detected using three 
different methods at the same facility found 0.7% of inpatients experienced an ADE when using 
voluntary reports, 9.6% using a computer monitoring program, and 13.3% using chart reviews.52 
Similarly, studies examining electronic health record data versus other means of detecting 
adverse drug events consistently found electronic health record data identified six to 10 times 
more ADEs than voluntary reporting systems,52–54 but identified approximately 20% fewer than 
manual chart review.52 Figure 1.2 shows the number of adverse drug event reports submitted to 
the FDA from 2010 through 2016 for warfarin, dabigatran, rivaroxaban, and apixaban.51 These 
voluntary reports were a fraction of a percent of annual prescriptions. As the U.S. population 
continues to age, more people will take more prescription medications.4 Until voluntary reporting 
improves to the point that all or most ADEs are captured, all available electronic data should be 
used to help reduce the occurrence of ADEs. 
1.9 Overview of the Dissertation 
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Currently there is no automated, free, non-proprietary model to predict bleeding risk 
among veterans prescribed OACs using readily available data from electronic health records. 
Prior research has focused on cohorts of patients based on diagnoses, and were conducted 
primarily in non-VA settings. Despite involvement in developing the National Action Plan for 
ADE Prevention and publishing a policy requiring monitoring and risk assessment of patients 
prescribed OACs, there are only a few studies on bleeding among veterans prescribed 
OACs.5,6,29,55–57 Veterans are a sizable population in the U.S., totaling about 20 million, or just 
over 6% of the U.S. population as a whole, with about 9 million enrolled in the VA health care 
system.58 Understanding the incidence and risk factors for gastrointestinal and intracranial 
bleeding among older veterans, and being able to predict bleeding risk could save lives, prevent 
hospitalizations, reduce healthcare costs, and contribute to reaching Patient Safety and National 
Action Plan goals, as well as complying with VHA policy.  
In order to meet these needs, three studies were conducted in conjunction with this 
dissertation using a cohort of veterans age 50 to 89 who received outpatient clinic services at a 
Veterans Integrated Service Network- (VISN-) 2 facility (New York and New Jersey) between 
10/01/2010 and 09/30/2015, with the following aims: 
1.9.a Specific Aims 
Aim 1: Describe the cumulative incidence and incidence rates of gastrointestinal and intracranial 
bleeding in a cohort of older veterans. Stratify cumulative incidence and incidence rates by 
subjects prescribed warfarin, DOACs, and no OACs, and use logistic regression to compare the 
odds of gastrointestinal and intracranial bleeding between these three groups. 
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Aim 2: Determine the time course of gastrointestinal and intracranial bleeding risk for older 
veterans prescribed OACs as time taking OACs increases, by identifying risk factors using a 
retrospective cohort design and time-to-event analysis. 
Aim 3: Develop, evaluate, and select models to predict risk of gastrointestinal and intracranial 
bleeding for older veterans prescribed OACs using machine learning tools, and compare model 
performance to the HAS-BLED, ATRIA, ORBIT, and QBLEED algorithms. 
1.9.b Innovation 
The three studies completed for this dissertation involved a retrospective cohort drawn 
from a clinical and administrative database of electronic health record data, rather than one 
compiled for clinical trials or other research purposes, resulting in a design that was closer to a 
population-based study (where the population was veterans) and was comprised of subjects who 
were more like the patients providers see in usual clinical practice. These three studies provide 
an update to previous research that was conducted prior to FDA approval of DOACs and the 
development of the ATRIA, QBLEED, and ORBIT bleeding risk algorithms. The study 
presented in Chapter 4 was also the first to use machine learning tools to develop bleeding risk 
models, and to compare machine learning models to traditional risk scores (HAS-BLED, 
ATRIA, QBLEED, and ORBIT). Finally, this research is the first to involve a multi-facility 
cohort of veterans to produce automated, free, non-proprietary models that can help both VA and 
non-VA healthcare organizations meet ADE prevention goals. 
1.9.c Methods and Data Overview 
The three research aims of this dissertation were accomplished with a retrospective 
cohort design using data from the Veterans Health Administration. The VHA is the largest 
integrated healthcare system in the U.S. and is comprised of 144 hospitals and 1,211 outpatient 
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clinics.59 It was the first system in the country to use a common electronic health record with 
system-wide information exchange.60 Data in the VHA corporate data warehouse dates back to 
October 1, 1998 and includes inpatient, outpatient, and emergency room encounter dates, 
diagnoses, lab test dates and results, prescription medication names, doses, and dates filled, 
demographics, 5-digit Zip code, and sociodemographic variables such as marital status, and 
insurance type. The VA delivered healthcare services to over 6.5 million Veterans in 2014,61 
including over 90 million outpatient visits and 700,000 inpatient admissions.61 The VISN-2 
network provides healthcare services to more than 500,000 veterans living in 76 counties in New 
York, New Jersey, and Pennsylvania.62 
Aim 1 analyses were conducted using the full cohort of subjects, while the analyses for 
Aims 2 and 3 were conducted using only subjects with a prescription for an OAC. The primary 
independent variable was the subject’s OAC prescription category: no OAC, warfarin, or DOAC. 
The primary dependent variable was a dichotomous variable indicating the presence of an 
ICD-9 or ICD-10 code for gastrointestinal or intracranial bleeding in the electronic health record 
(see Appendix 1 for a list of included ICD-9 and ICD-10 codes). The codes used in all three 
studies were the same, replicating code lists from previous research.27,34,63,64 Diagnosis codes for 
bleeding were associated with any type of clinical encounter, including inpatient admissions, 
outpatient visits, or emergency room visits. Each subject’s index date was the date of the first 
outpatient clinical encounter from October 1, 2010 to September 30, 2011 for the first study, and 
the first OAC prescription date on or after October 1, 2010 for the second and third studies. The 
cohort was drawn from patients with at least two primary care visits between October 1, 2010 
and September 30, 2011 at a VISN-2 facility and assigned a primary care provider. The cohort 
was selected in this way because subjects with two or more outpatient encounters and an 
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assigned primary care provider were more likely to receive regular care through the VA, and also 
have the most complete clinical and administrative data for analysis. 
A diagnosis of atrial fibrillation is the most common reason why patients are prescribed 
OACs,32 and risk of atrial fibrillation increases after age 50,32 therefore the age range for 
inclusion in the study was 50 to 89. Cohort exclusion criteria were: (1) a prescription for an OAC 
in the six months prior to index, in order to include only subjects with an incident OAC 
prescription, or the first prescription after a long period of non-use. This six month exclusion was 
consistent with prior research.34 And (2) a Continental U.S.-based 5-digit Zip code, in order to 
allow for augmentation of the VHA dataset with data from the National Center for Health 
Statistics and American Community Survey (ACS).  
The National Center for Health Statistics (NCHS) assigns a percent rural designation to 
counties in order to allow researchers to study the effects of urban versus rural residence.65 The 
cohort of veterans who were the subjects of the studies included in this dissertation resided 
primarily in New York, New Jersey, and Pennsylvania, all states that include both very urban 
and very rural areas. There were too many counties represented in the cohort to use county as a 
categorical variable, but the use of the percent rural value assigned by NCHS allowed the 
inclusion of a variable to account for geographic location. The relationship between health 
outcomes and geography is well documented,66 so inclusion of a geographic variable portrayed a 
more holistic view of subjects. Subjects were matched by county of residence to the 2013 NCHS 
percent rural designation – a continuous value ranging from zero to 100. 
The ACS replaced the Census Bureau long-form survey in 2010, and is the main means 
for collecting demographic and social data on the U.S. population.67 Each subject’s 5-digit Zip 
code of residence was matched to the 2012 ACS data on the following five Zip code-level 
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variables: (1) percent living in overcrowded conditions (defined as more than one occupant per 
room), (2) percent unemployment, (3) percent with no access to a car, (4) percent of renter-
occupied dwellings, and (5) median household income.67 The first four of these ACS variables 
were used to calculate the Townsend score, and were represented as continuous numeric values 
from zero to one. 
The Townsend score is a population measure that estimates material deprivation,68 and 
has been used in the U.K. for many years to estimate relative deprivation and measure 
correlations between deprivation and health status.34,69 The Townsend score is an unweighted 
sum of measures 1-4 above. The Townsend score has been shown to correlate well with health-
related measures such as overall health, depression, and long-term illness.69 Another study found 
that median household income approximated deprivation as well as the Townsend score,70 and 
studies from both the U.K. and U.S. found the Townsend score may be less indicative of relative 
deprivation in urban than rural communities.69–72 Zip code-level median household income was 
included as a study variable in order to provide another estimate of socioeconomic status, since 
many of the veterans in the cohort lived in urban areas, Townsend score may not be an accurate 
measure of relative deprivation. A priori it was unknown whether Townsend score or median 
household income would be a significant factor associated with gastrointestinal and intracranial 
bleeding in the study cohort.  
There are several methods for calculating Therapeutic Time in Range (TTIR) using 
results of INR lab tests of subjects prescribed warfarin. Three of the most common methods used 
in clinical trials are fraction of INRs, cross-sectional, and Rosendaal.73 Fraction of INRs in range 
is calculated by dividing the number of INRs in the target therapeutic range by the total number 
of INRs during the time period of study.73 The cross-sectional method is calculated in a manner 
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similar to fraction of INRs but for a designated day, plus or minus 7 days.73 Rosendaal linear 
interpolation is a longitudinal method incorporating person-time, and uses a designated interval 
between tests and a maximum number of days to carry the interpolated value forward in time, in 
the absence of another test result.73 The main disadvantages of the Rosendaal method are the 
assumptions made about test interval and carry forward time, which likely will not apply to all 
patients in the calculation. 
Few published studies on warfarin and bleeding described how TTIR was calculated, 
however most clinical trials used the Rosendaal method.74,75 The only study identified that 
compared the three most common methods on the same population found the fraction of INRs 
and cross-sectional methods produced similar results, but the Rosendaal method produced 
significantly lower TTIR results for two-, three-, and six-month intervals.73 For the purposes of 
this dissertation, TTIR was calculated for each subject who was prescribed warfarin using the 
fraction of INRs method for each year of the study. The reason for using fraction of INRs was to 
simplify calculations, and because TTIR is a variable for only one of the bleeding risk score 
comparators (HAS-BLED) for the study presented in Chapter 4.  
1.9.d Conceptual and Theoretical Frameworks 
The Data Science process (Figure 1.3) is a conceptual framework that influenced the 
goals and process of this dissertation. Data Science is an approach that combines statistics, 
machine learning, computer programming, data visualization, and domain expertise to provide 
information for decision making and produce data products.76 The first step of the Data Science 
process is collecting or obtaining data, followed by data processing. What makes this different 
from traditional approaches to research is that the data scientist uses computer programming – 
usually Structured Query Language (SQL) or Python – to collect and process large amounts of 
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electronic data.76 Instead of requesting a dataset or finding an existing dataset, the data scientist 
extracts the data from the source, and in the course of doing so makes decisions about processing 
– constructing variables as categorical, numeric, dichotomous, etc. For the studies presented in 
this dissertation, SQL was used to select the study cohort from the VA Corporate Data 
Warehouse according to the criteria in section 1.9.c Methods and Data Overview. An initial SQL 
query returned the cohort with demographic variables and index date. Subsequent queries were 
written to join comorbidities, prescriptions, outcomes, and TTIR calculations to the cohort 
dataset. This iterative approach to building the cohort dataset with multiple SQL queries was 
necessary due to computer processing limitations and VA rules for accessing the data warehouse.  
The aims of the dissertation research built on one another. Aim 1 sought to define the 
scope of the problem of gastrointestinal and intracranial bleeding among older veterans. Aim 2 
sought to determine risk factors and time-to-event for gastrointestinal and intracranial bleeding. 
These provided the foundation for Aim 3, the completion of which produced a data product in 
the form of a free, non-proprietary model that can be automated and is available to any 
healthcare facility to use for self-monitoring, benchmarking, and quality improvement, with the 
goal of predicting risk of gastrointestinal or intracranial bleeding following prescription of an 
OAC. The more healthcare organizations use the predictive model the greater the opportunity for 
aggregate data collection, creation of a feedback loop, and new data for ongoing refinement of 
models as they degrade. 
Data Science is a relatively new discipline that has been successfully applied to finance, 
marketing, Internet services (e-mail spam filters and consumer recommendations), and genomic 
and cancer research.76 Data Science as a discipline often focuses on the discovery of previously 
unknown or novel relationships within large datasets, whereas classical biomedical statistics 
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tends to be hypothesis driven. The dissertation research applied the Data Science process – 
including data collection, synthesis, predictive modeling, and independent validation of a 
predictive model – to the problem of gastrointestinal and intracranial bleeding among veterans to 
facilitate compliance with patient safety goals and directives. 
 This dissertation was also informed by the Ecosocial Theory of Epidemiology,77 
especially in terms of variables selected for inclusion in the studies. Ecosocial theory, a 
multilevel approach, seeks to uncover the causes of population health disparities through the 
examination of variables interacting on multiple levels and how they create an ecosystem that 
influences health.78 Ecosocial theory seeks to explore how membership in various groups leads 
to population patterns of health, and because its view of society is dynamic, it is a model that can 
scale down to the genomic level or up to a global health view.78 Figure 1.4 uses a vertical fractal 
to illustrate the multi-level concept of Ecosocial Theory. To draw an example from the 
dissertation, a subject could hypothetically have a genetic biomarker predisposing him to certain 
types of cancer, making him a member of a group of subjects with that genetic biomarker. He 
may also have a diagnosis of congestive heart failure, making him a member of a group of 
subjects with that diagnosis. He is also a member of various groups based on his individual 
characteristics, including those related to socioeconomic status, such as race, insurance coverage, 
or disability category. He is also a member of various groups based on the characteristics of the 
five-digit Zip code where he lives, and he is a member of a group of veterans. Being a part of 
these different groups influences health in different ways, but membership in these groups can 
change as individual, neighborhood-level, or even veteran-level characteristics change. When 
viewed in this way the social determinants of health become less a final explanation of health 
outcomes (poor health status due to race or socioeconomic status), and more of a starting point 
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for exploring the societal and environmental conditions that led to the poor health outcome in a 
particular population. Ecosocial Theory encourages questions that require a multi-level 
examination of social and environmental factors that impact health,77,78 such as how a policy 
decision impacted a racial group and contributed to a health outcome. Other examples include 
hospital ownership, pollution, and de facto segregation. Ecosocial Theory, in conjunction with 
the literature, influenced the selection of variables for the dissertation studies. A list of study 
variables is shown in table 1.2. 
1.9.e Hypotheses 
Aim 1: Describe the cumulative incidence and incidence rates of gastrointestinal and intracranial 
bleeding among older veterans. Stratify cumulative incidence and incidence rates by subjects 
prescribed warfarin, DOACs, and no OACs, and use logistic regression to compare the odds of 
gastrointestinal and intracranial bleeding between these three groups. 
 Hypotheses: 
(1) Cumulative incidence and incidence rates of gastrointestinal and intracranial 
bleeding will be comparable to previous studies. 
(2) Cumulative incidence and incidence rates of gastrointestinal and intracranial 
bleeding will be higher among subjects prescribed DOACs compared to those 
prescribed warfarin. 
Aim 2: Determine the time course of gastrointestinal and intracranial bleeding risk for older 
veterans prescribed OACs as time taking OACs increases, by identifying risk factors using a 




(1) Variables estimating socioeconomic deprivation – Townsend score and 
median household income by Zip code – will be significant risk factors for 
gastrointestinal and intracranial bleeding. 
(2) Being prescribed an OAC for a longer period of time will be associated with 
increased risk of gastrointestinal or intracranial bleeding. 
Aim 3: Develop, evaluate, and select models to predict risk of gastrointestinal and intracranial 
bleeding for older veterans prescribed OACs using machine learning tools, and compare model 
performance to the HAS-BLED, ATRIA, ORBIT, and QBLEED algorithms. 
 Hypotheses: 
(1) One or more algorithms produced using machine learning will accurately 
predict gastrointestinal and intracranial bleeding, with a sensitivity of 80% or 
greater and a positive predictive value of 75% or greater. 
(2) Machine learning algorithms will perform better than the traditional 
algorithms to which they are compared (HAS-BLED, ATRIA, ORBIT, and 
QBLEED) at predicting risk of gastrointestinal and intracranial bleeding. 
1.9.f Organization of the Dissertation 
 The dissertation is organized into five chapters, including this introductory chapter, 
Chapter 1. The study presented in Chapter 2 describes the cumulative annual incidence per 1,000 
veterans who experienced gastrointestinal and intracranial bleeding stratified by OAC 
prescription category (no OAC, warfarin, or DOAC), incidence rate per 100 person-years for the 
5-year study period by OAC prescription category, and odds of experiencing a gastrointestinal or 
intracranial bleeding event by OAC category using logistic regression (Aim 1). The study 
presented in Chapter 3 identifies risk factors for gastrointestinal and intracranial bleeding, and 
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calculates the relative risk of bleeding over time for veterans with an OAC prescription using 
time-to-event analysis (Aim 2). The study presented in Chapter 4 compares models to predict 
risk of gastrointestinal and intracranial bleeding for veterans prescribed an OAC using logistic 
regression and machine learning tools (Aim 3). Chapter 5 presents a summary and synthesis of 
the findings from the studies presented in Chapters 2 through 4, discussion of the policy and 

































Figure 1.1. Prescription Trends for Warfarin and Three DOACs (Dabigatran, Rivaroxaban, and 





Figure 1.2. Trends in Adverse Event Reporting to FDA for Warfarin and Three DOACs 






































Age     X   
Age > 65 X X     
Age >= 75       X 
Alcohol Use/Abuse X   X   
Anemia       X 
Antidepressants     X   
Antiplatelet Medication     X X 
Atrial Fibrillation     X   
Cancer     X   
Carbamazepine^     X   
Congestive Heart Failure   X X   
Corticosteroids     X   
Diabetes   X     
Drug Use/Abuse X       
Ethnicity     X   
Female Gender   X     
History of Bleeding X   X X 
History of Stroke X X     
Hypertension X X X   
Liver or Renal Disease X X X X 
Low Platelet Count     X   
NSAIDS*     X   
Phenytoin^     X   
Smoker     X   
TTIR < 60%** X       
Townsend score     X   
Venous 
Thromboembolism     X   
*NSAIDS are nonsteroidal anti-inflammatory drugs. ^Carbamazepine and phenytoin are 
anticonvulsant medications. **TTIR is therapeutic time in range for an International Normalized 









Table 1.2. Study Variables and Definitions. 
Variable Name Type and Definition Values 
Primary Independent Variable 
OAC Category 
Categorical- describes the subject's first OAC 




   Warfarin 
Dichotomous- subject had a prescription for warfarin 
on/after index date (descriptive only; not used for 
modeling) Yes/No 
   Dabigatran 
Dichotomous- subject had a prescription for this DOAC 
on/after index date (descriptive only; not used for 
modeling) Yes/No 
   Rivaroxaban 
Dichotomous- subject had a prescription for this DOAC 
on/after index date (descriptive only; not used for 
modeling) Yes/No 
   Apixaban 
Dichotomous- subject had a prescription for this DOAC 
on/after index date (descriptive only; not used for 
modeling) Yes/No 
Primary Dependent Variable 
Bleeding Event 
Dichotomous- subject had a diagnosis code for bleeding 
after the index date Yes/No 
   Bleeding Type 
Categorical- type of bleeding the subject experienced 




Other Explanatory Variables 
Demographic 
Age Continuous- subject's age in years at index Integer 
Age >= 75 
Dichotomous- subject's age was greater than or equal 
to 75 years at index Yes/No 
Gender Subject's reported gender Male/Female 
Marital Status Subject's reported marital status 
Married (or separated) 
Not Married (never 
married, divorced, 
widowed, unk/missing) 
Race/Ethnicity Subject's combined reported race/ethnicity 
White Non-Hispanic 
Non-White (American 
Indian or Alaska Native, 
Asian, Black Non-Hispanic, 
Hispanic or Latino, Multiple 
races, Native Hawaiian or 




Smoker Subject's reported smoking status 
Yes (current smoker) 
No (former or never 
smoker, unk/missing) 
Obese Dichotomous- subject had BMI >= 30% Yes/No (unk/missing) 
Months of 
Observation 
Continuous- number of months the subject contributed 
to the study, from index date to censor date (bleeding 
event, death, or end of study) Integer 
Time-to-Event 
Continuous- number of days from the subject's first 
OAC prescription date to censor date (bleeding, death, 
or end of study) Numeric 
Socioeconomic 
Disability 
Dichotomous- the subject had a Military Service-
Connected Disability Yes/No 
Insurance Coverage 
Dichotomous- the subject had health insurance 
(private, Medicare, or Medicaid) Yes/No 
Exempt from VA 
Copayment 
Dichotomous- the subject was not required to pay an 
out-of-pocket copayment for VA health services Yes/No 
Townsend Score* 
Continuous- unweighted sum of percent unemployed, 
percent overcrowding, percent with no vehicle, and 
percent renter-occupied at the 5-digit Zip code level  Numeric 
Median Household 
Income* Continuous- at the 5-digit Zip code level Numeric 
Geographic 
Percent Rural** 
Continuous- percent of geographic area in county of 
residence considered rural Numeric 
Co-prescriptions 
Aspirin 
Dichotomous- subject had a prescription for this 




Dichotomous- subject had a prescription for this 
medication at any time prior to index Yes/No 
NSAIDS 
Dichotomous- subject had a prescription for this 
medication at any time prior to index Yes/No 
Steroids 
Dichotomous- subject had a prescription for this 
medication at any time prior to index Yes/No 
Statins 
Dichotomous- subject had a prescription for this 
medication at any time prior to index Yes/No 
Antidepressants 
Dichotomous- subject had a prescription for this 
medication at any time prior to index Yes/No 
Amiodarone 
Dichotomous- subject had a prescription for this 
medication at any time prior to index Yes/No 
Carbamazepine 
Dichotomous- subject had a prescription for this 




Dichotomous- subject had a prescription for this 
medication at any time prior to index Yes/No 
Antifungals 
Dichotomous- subject had a prescription for this 
medication at any time prior to index Yes/No 
Number of 
Prescriptions Continuous- count of active prescriptions at index Integer 
Comorbidities 
Diabetes 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Congestive Heart 
Failure 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Hypertension 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Atrial Fibrillation 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Chronic Kidney 
Disease 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Liver Disease 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Chronic Pancreatitis 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Stroke 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this condition at any time prior to index Yes/No 
Pulmonary Embolism 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this condition at any time prior to index Yes/No 
Deep Vein Thrombosis 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this condition at any time prior to index Yes/No 
Cancer 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Esophageal Varices 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this disease at any time prior to index Yes/No 
Ulcer 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this condition at any time prior to index Yes/No 
Acute Myocardial 
Infarction 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this condition at any time prior to index Yes/No 
Alcohol Abuse 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
this condition at any time prior to index Yes/No 
History of Bleeding 
Dichotomous- subject had an ICD-9 or ICD-10 code for 
bleeding at any time prior to index Yes/No 
Blood Tests and Medical Procedures 
Low Platelet Count 
Dichotomous- subject had a lab result value < 





Dichotomous- subject had ICD-9 or ICD-10 procedure 
code or CPT code any time prior to index Yes/No 
Bleeding Risk Scores 
HAS-BLED Sum of points based on algorithm Integer 
ORBIT Sum of points based on algorithm Integer 
ATRIA Sum of points based on algorithm Integer 
*Data source: American Community Survey 
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2.1 Background 
Adverse drug events affect 5-10% of inpatients,1,80–82 1-3% of emergency room 
patients,1,83,84 and 25-35% of clinic outpatients.52,85 Adverse drug events increase morbidity and 
cost $76 billion per year.3 One of the drug classes most commonly associated with adverse drug 
events is OACs, the use of which can cause life-threatening adverse events such as 
gastrointestinal and intracranial bleeding.4,14,34 OACs are often prescribed to patients with atrial 
fibrillation, deep vein thrombosis, pulmonary embolism, mechanical heart valves, or following 
acute myocardial infarction to help prevent the formation of blood clots and further morbidity.12 
Gastrointestinal bleeding is the most common adverse outcome associated with OAC use, and 
intracranial bleeding is the most likely to be permanently disabling or fatal.14,86  
Warfarin has been the most commonly used OAC for more than 60 years and is effective, 
but puts patients at risk for bleeding.15 Previous studies found incidence rates for gastrointestinal 
bleeding of 3.71 per 100 person-years, and for intracranial bleeding of 0.67 per 100 person-years 
among subjects prescribed warfarin.27 Another study found an incidence rate of 0.78 per 100 
person-years for intracranial bleeding among veterans age 75 or older prescribed warfarin.56  
Direct OACs (DOACs), first approved by the U.S. Food and Drug Administration in 
2010, require less time to reach a therapeutic blood level after administration than warfarin, and 
do not require regular blood testing.25 Studies have shown that DOACs remain in the 
bloodstream longer in older adults.27 A recent retrospective cohort study found the risk of 
gastrointestinal bleeding was lower in patients prescribed DOACs versus those prescribed 
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warfarin, though in patients older than 75 this finding was reversed.27 The same study found an 
incidence rate of 1.66 and 4.1 per 100 person-years for gastrointestinal bleeding among those 
prescribed rivaroxaban and dabigatran (two DOACs), respectively.27  Two recent meta-analyses 
had contradictory findings: one found the risk of gastrointestinal bleeding was increased for 
those taking DOACs versus warfarin when the indication was acute myocardial infarction or 
prevention of venous thrombosis;9 while the other found lower rates of major and fatal bleeding 
in patients with atrial fibrillation or acute venous thromboembolism who were given DOACs.28 
Studies published using clinical trials data showed half of clinical trials of DOACs excluded 
patients who had risk factors or conditions predisposing them to bleeding, making the patient 
populations studied less like those seen by providers in usual clinical practice.9,28,29,87 
Many studies describing incidence or risk of bleeding associated with OACs are limited 
to subjects with a specific diagnosis, such as atrial fibrillation or venous thromboembolism. In 
addition, previous studies defined bleeding differently in terms of diagnoses or clinical criteria 
(lab values or a blood transfusion) to be met in order for a bleeding event to be counted in the 
outcome. These factors make it difficult to compare results across studies. No recent studies 
examining a broad category of bleeding or comparing incidence of bleeding in veterans 
prescribed warfarin versus DOACs or no OACs were identified. 
The objectives of this study were to describe and compare the cumulative incidence, 
incidence rates, and odds of gastrointestinal and intracranial bleeding in veterans age 50 to 89 
who were prescribed warfarin, DOACs, or no OACs using a retrospective cohort design. This 
study was approved by the U.S. Department of Veterans Affairs (VA), Veterans Integrated 
Service Network- (VISN-) 2 Institutional Review Board, Research and Development Committee, 
and Safety Committee. 
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2.2 Data and Methods 
2.2.a Participants and Data Source 
Subjects included in the study were veterans age 50 to 89 with a five-digit Zip code, at 
least two primary care visits at a VISN-2 facility between October 1, 2010 and September 30, 
2011, and assigned a primary care provider. The VISN-2 network includes 14 hospitals and 57 
Community Based Outpatient Clinics in New York and New Jersey, and one Community Based 
Outpatient Clinic in Pennsylvania.62 The first visit on or after October 1, 2010 was used as the 
index date for when the subject joined the cohort. The cohort was comprised of 131,135 subjects. 
One subject was excluded due to having a non-U.S. based Zip code, and 384 were excluded for 
having a prescription for an OAC in the six months prior to index, resulting in 130,750 patients 
included in the analyses. The study period was October 1, 2010 through September 30, 2015, for 
a total of five Federal fiscal years – the common reporting cycle for the VA. The 130,750 
subjects contributed 614,196 person-years of observation time to the study. Nearly 96% 
(n=124,946) of subjects were followed until the end of the study.  
2.2.b Study Variables 
The primary dependent variable was the presence of an ICD-9 or ICD-10 Code for 
gastrointestinal or intracranial bleeding (see Appendix 1), recorded in the dataset as dichotomous 
variables (one for each type of bleeding event). The primary independent variable was a 
categorical variable for OAC prescription (warfarin, DOAC, or no OAC). Direct OACs included 
in the study were dabigatran, rivaroxaban, and apixaban. Subjects included in the cohort did not 
have a prescription for any OAC in the six months prior to their index date. Other explanatory 
variables were insurance coverage; prescriptions for aspirin, non-aspirin antiplatelet medications, 
or non-steroidal anti-inflammatory drugs (NSAIDS); and diagnosis of hypertension, chronic 
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kidney disease, liver disease, history of stroke or bleeding (see Appendix 2 for a list of ICD-9 
and ICD-10 codes), congestive heart failure, diabetes, atrial fibrillation, deep vein thrombosis, 
pulmonary embolism, cancer, ulcer, esophageal varices, acute myocardial infarction, alcohol 
abuse, or heart valve replacement – all as dichotomous variables. Age and number of 
prescriptions at index date were included as continuous variables, and gender, body mass index 
(BMI), marital status, smoking status, service-connected disability, exempt from VA copayment 
(an indicator of low income), and race/ethnicity were included as categorical variables. 
2.2.c Approaches to Determining Bleeding Risk Exposure 
There was no standard research practice identified for determining when bleeding risk 
exposure begins after OAC prescription fill or first dose date. This was true of clinical trials as 
well. Previous studies used zero, 3, 4, 5, or 7-days.63,86–90 Despite research showing that new 
users of warfarin have a higher risk of bleeding in the first 30 days of use,19,20 many clinical trials 
only included subjects who had been prescribed warfarin for at least 180 days and had stable 
International Normalized Ratio levels.29,33,35 Other studies counted all bleeding events after a 
minimum of 1 dose of an OAC, regardless of type (warfarin or DOAC).19,20,88,89 Due to this lack 
of consistency, two approaches were used to determine if subjects were classified as having an 
OAC prescription at the time of a bleeding event. 
The first approach was to count any OAC prescription that preceded a bleeding event, 
regardless of OAC type, even if the bleeding event was the next day. This approach is referred to 
in the results as “no blackout period.” The second approach was to classify subjects as having a 
prescription for an OAC at the time of a bleeding event only if the prescription preceded the 
bleeding event by five or more days, referred to in the results as “5-day blackout period.” 
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The five day time period was chosen based on the fact that warfarin takes 2 – 7 days to 
reach therapeutic blood levels.11,91 In contrast, DOACs are effective in much shorter time 
periods, generally less than 24 hours from the first dose.25 The OAC prescription date used in the 
current study was the date when the filled prescription was given to the subject, so while this 
should provide a date and time close to the administration of the first dose (lacking that exact 
date and time), there may still be a time lag. 
2.2.d Analysis Approach 
Cumulative incidence of gastrointestinal and intracranial bleeding was calculated for each 
year of the study to compare groups by OAC category, and to examine trends over time using 
both the no blackout and 5-day blackout period approaches. Cumulative incidence was 
calculated using the following formula:92 
Cumulative incidence = Number of bleeding events 
        Number of subjects 
 
The incidence rate per 100 person-years over the 5-year study period was calculated for 
all subjects comparing the no blackout and 5-day blackout period approaches using the following 
formula:92 
Incidence Rate =  Number of bleeding events 
     Person-time 
 
 
Odds of experiencing a bleeding event were calculated using logistic regression for both 
approaches. Due to their small numbers, gastrointestinal and intracranial bleeding events were 
grouped together for regression analyses. The formula for logistic regression with multiple 








Unadjusted regression models were developed for all subjects and stratified by gender 
using both approaches; then adjusted regression models were developed for all subjects using 
both approaches, and covariates significant at the 0.05 level are shown. Analyses were completed 
using R version 3.4.1 and Microsoft Excel 2013. 
2.3       Results  
 The cohort included 130,750 subjects. Ninety-six percent (n=126,232) of subjects were 
male, 53% (n=69,938) were married, 84% (n=110,409) had insurance, and 75% (n=98,007) were 
White Non-Hispanic (3.37% missing). Only four percent (n=5,010) of subjects had a new 
prescription for an OAC during the study period, while 10% (n=13,060) had a new or renewed 
prescription for aspirin, 6% (n=8,041) for non-aspirin antiplatelet medications, and 31% 
(n=40,423) for NSAIDS. Thirty-five percent (n=45,873) of the cohort never smoked. Fifteen 
percent (n=19,366) were obese (BMI > 30), but 66% (n=86,661) of the cohort were missing 
height, weight, or both, so BMI could not be calculated. Chronic conditions were common in the 
cohort: 83% (n=108,975) had a diagnosis of hypertension, 41% (n=53,905) had a diagnosis of 
diabetes, 10% (n=12,505) had a diagnosis of congestive heart failure, 30% (n=39,096) had a 
diagnosis of cancer, and 36% (n=47,634) had a diagnosis indicating prior bleeding (see 
Appendix 2 for a list of ICD-9 and ICD-10 codes). Thirteen percent of the cohort (n=17,390) had 
a diagnosis of atrial fibrillation. Table 2.1 further describes the cohort. 
 Fewer than six percent of subjects experienced a bleeding event (n=7,250) or died (n=41) 
during the study period. Table 2.2 shows the number of subjects and events over the five years of 
the study by OAC category. Table 2.3 shows how the approach to OAC classification had an 
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impact on category assignment among study subjects. This helps to illustrate the differences in 
the findings using the two approaches that follow. 
 Figure 2.1 compares the cumulative incidence of gastrointestinal bleeding per 1,000 
veterans by OAC category and year using the two approaches. Figure 2.2 compares the annual 
incidence of intracranial bleeding per 1,000 veterans by OAC category and year using the two 
approaches. Using the no blackout period approach subjects followed an expected pattern with 
cumulative gastrointestinal bleeding incidence being lowest among subjects with no OAC 
prescription. Subjects with a prescription for DOACs fell in the middle of the three groups in 
terms of cumulative incidence using this approach, and subjects with a prescription for warfarin 
had the highest cumulative incidence. Using a 5-day blackout period, subjects with a prescription 
for DOACs had lower cumulative incidence of gastrointestinal bleeding than subjects with no 
OAC prescription for the first four years of the study, and cumulative intracranial bleeding 
incidence among subjects prescribed DOACs was lower than subjects prescribed no OACs in 
years 1, 2, 3, and 5 using this approach. Both approaches illustrate a trend in increased 
cumulative incidence of gastrointestinal bleeding among veterans prescribed OACs over the five 
years of the study. 
 Subjects prescribed no OACs had low cumulative incidence of intracranial bleeding 
using both approaches, and cumulative incidence remained relatively flat over the five years of 
the study. Using the no blackout period approach subjects prescribed warfarin had cumulative 
intracranial bleeding incidence that increased and decreased in alternating years, but was similar 
in the last year of study to the first year of study. Subjects prescribed DOACs also had an up and 
down pattern, but ended the five years higher than the first or third years of the study. Using a 5-
day blackout period subjects prescribed warfarin had a spike in cumulative intracranial bleeding 
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incidence in year three, and increased incidence over years 1, 2, and 4. Subjects prescribed 
DOACs had relatively flat cumulative incidence of intracranial bleeding, and in years 1, 3, and 5, 
had lower cumulative incidence than subjects prescribed no OACs. 
 Table 2.4 shows a comparison of incidence rates per 100 person-years between the no 
blackout and 5-day blackout period approaches. The time period for these rates is the five years 
of the study. The incidence rate for either type of bleeding per 100 person-years using no 
blackout period was 1.13 for subjects not prescribed OACs, 1.82 for subjects prescribed DOACs, 
and 2.70 for subjects prescribed warfarin. The incidence rate for either type of bleeding per 100 
person-years using a 5-day blackout period was 1.17 for subjects not prescribed OACs, 0.72 for 
subjects prescribed DOACs, and 1.61 for subjects prescribed warfarin. Using no blackout period 
the rate per 100 person-years for gastrointestinal bleeding for subjects prescribed no OACs was 
1.01, and for intracranial bleeding was 0.12. For subjects prescribed DOACs the rate per 100 
person-years for gastrointestinal bleeding was 1.53, and for intracranial bleeding was 0.29. For 
subjects prescribed warfarin the rate per 100 person-years for gastrointestinal bleeding was 2.36, 
and for intracranial bleeding was 0.34. Using a 5-day blackout period the rate per 100 person-
years for gastrointestinal bleeding for subjects prescribed no OACs was 1.04, and for intracranial 
bleeding was 0.13. For subjects prescribed DOACs the rate per 100 person-years for 
gastrointestinal bleeding was 0.62, and for intracranial bleeding was 0.10. For subjects 
prescribed warfarin the rate per 100 person-years for gastrointestinal bleeding was 1.42, and for 
intracranial bleeding was 0.19. Figure 2.3 visualizes the incidence rates listed in Table 2.4, using 
a whisker plot to illustrate the differences in rates using the two approaches, indicating statistical 
significance for the pairs of rates (no blackout and 5-day blackout by bleeding type and OAC 
category) where confidence intervals do not overlap. 
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 Tables 2.5 and 2.6 show the results of unadjusted logistic regression models using the no 
blackout period and 5-day blackout period approaches for all subjects and stratified by gender. 
The unadjusted logistic regression model with no blackout period found subjects prescribed 
DOACs had 1.66 the odds of gastrointestinal or intracranial bleeding compared to subjects 
without an OAC prescription, and subjects prescribed warfarin had 2.53 the odds of 
gastrointestinal or intracranial bleeding compared to subjects without an OAC prescription. This 
was true for male subjects as well, but the findings for female subjects was not statistically 
significant. The unadjusted logistic regression model with a 5-day blackout period found subjects 
with a prescription for DOACs had 0.62 the odds of gastrointestinal or intracranial bleeding 
compared to subjects without an OAC prescription, and subjects prescribed warfarin had 1.42 the 
odds of gastrointestinal or intracranial bleeding compared to subjects without an OAC 
prescription. These findings were similar among male subjects, but for female subjects the 
results were not statistically significant. 
 Tables 2.7 and 2.8 show the results of logistic regression models adjusted for the 
covariates listed in Table 2.1. Results are shown for all subjects, along with covariates that were 
significant at the 0.05 level. The adjusted logistic regression model using no blackout period 
found subjects prescribed warfarin had 1.47 the odds of gastrointestinal or intracranial bleeding 
compared to subjects without an OAC prescription, and subjects prescribed DOACs had 1.30 the 
odds of gastrointestinal or intracranial bleeding compared to subjects without a prescription for 
OACs. Other statistically significant covariates were history of bleeding, esophageal varices, 
stroke, ulcer, and a concurrent prescription for aspirin or non-aspirin antiplatelet medications. 
The adjusted logistic regression model using a 5-day blackout period found subjects prescribed 
warfarin had 0.72 the odds of gastrointestinal or intracranial bleeding compared to subjects 
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without a prescription for OACs, and subjects prescribed DOACs had 0.42 the odds of 
gastrointestinal or intracranial bleeding compared to subjects without an OAC prescription. 
Other statistically significant covariates were similar to the adjusted model with no blackout 
period. 
2.4 Discussion 
 This study produced four main findings. First, gastrointestinal and intracranial bleeding 
was not common in this cohort of older veterans (5.54%). Second, the approach taken (no 
blackout period versus 5-day blackout period) had a significant impact on the results of 
cumulative incidence, incidence rate, and odds calculations. Third, cumulative incidence of 
gastrointestinal and intracranial bleeding among subjects prescribed no OACs was higher than 
expected. Fourth, incidence rates per 100 person-years for gastrointestinal and intracranial 
bleeding among subjects prescribed DOACs or warfarin was lower than previous studies. 
 Gastrointestinal bleeding in the general population is estimated at 25 to 100 events per 
100,000 people (depending on the bleeding site),93 while intracranial bleeding in the general 
population is estimated at 12 to 15 events per 100,000 people of all ages, and as high as 350 
events per 100,000 in the elderly with hypertension.94 The subjects in this study who were not 
prescribed OACs experienced an average of 9 to 10 times the number of gastrointestinal bleeding 
events, and an average of 7 to 8 times the intracranial bleeding events as would be expected in 
the general population. Unfortunately, no studies were identified that focused on gastrointestinal 
or intracranial bleeding in veterans who were not prescribed OACs, so there is not a good 
historical comparison. 
 Using both the no blackout and 5-day blackout period approaches this study found lower 
incidence rates per 100 person-years for gastrointestinal and intracranial bleeding among 
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subjects prescribed OACs than in previous studies on non-veteran populations.14,27,56 This study 
also found lower odds of bleeding among subjects prescribed OACs (using both approaches) 
than a previous meta-analysis of randomized, controlled trials involving non-veteran 
populations.9 
 An important finding of this study was the difference in results between the no blackout 
period and the 5-day blackout period approaches. Using no blackout period, subjects prescribed 
warfarin who experienced bleeding events prior to the time when warfarin had likely reached a 
therapeutic level were counted as having the outcome, and therefore the cumulative incidence, 
incidence rate, and odds of bleeding among subjects prescribed warfarin using this approach 
appeared higher than it probably was. Using a 5-day blackout period, subjects prescribed 
DOACs who experienced bleeding events during the blackout period were not counted as having 
the outcome, even though DOACs reach a therapeutic level much faster than warfarin, so the 
cumulative incidence, incidence rate, and odds of bleeding among subjects prescribed DOACs 
using this approach appeared lower than it probably was. Both approaches had the potential of 
introducing classification bias into a portion of the study population in terms of the OAC 
category to which they were assigned. A better approach to blackout period could be a hybrid of 
the two compared here: to use no blackout period for subjects prescribed DOACs, and a 5-day 
blackout period for subjects prescribed warfarin. Approached in this way, there would be no 
statistically significant difference in incidence rate per 100 person-years between those 
prescribed DOACs and warfarin. The implications of this finding are that studies should be 
examined carefully to determine how bleeding events were counted before extrapolating results 
to different populations and implementing interventions in clinical practice, as the results of 
studies using different blackout periods are not directly comparable.  
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 This study found a higher cumulative incidence of gastrointestinal and intracranial 
bleeding among subjects not prescribed any OACs than previous studies on the general 
population, but found lower incidence rates per 100 person-years, and lower odds of both 
gastrointestinal and intracranial bleeding among subjects prescribed warfarin or DOACs than 
previous studies. 
2.5 Limitations 
 This study had several limitations. Data used in this study came from a clinical and 
administrative database, and did not include non-VA insurance claims or pharmacy benefit data, 
so services and prescriptions obtained outside the VA healthcare system were not included, 
although every effort was made to include those veterans who appeared to receive care at the VA 
as their primary site of care. Subjects for this study were chosen based on outpatient utilization 
rather than on hospitalization and subsequent OAC prescription. It’s possible that using a post-
hospitalization cohort would have yielded different results. The subjects in this study were 
overwhelmingly male, so it’s uncertain how applicable findings from this study are to female 
veterans. The subjects included in this study primarily lived in New York and New Jersey, and 
regional differences in demographics may limit the generalizability of findings to other parts of 
the United States. This study didn’t include different OAC doses, changes in dose, or changes 
from one OAC to another. Finally, this study only examined the impact of two different blackout 
periods to determine OAC prescription category, and it is possible that other blackout periods 
would result in different findings, although this study may be the first to identify how differences 




 This study used two different approaches to compare the cumulative incidence, incidence 
rate, and odds of gastrointestinal and intracranial bleeding over five years among a cohort of 
veterans prescribed no OACs, DOACs, and warfarin, who received care at New York and New 
Jersey VA healthcare facilities. The blackout period used to categorize subjects in terms of OAC 
prescription had a significant impact on results. Cumulative incidence of gastrointestinal and 
intracranial bleeding among those not prescribed any OACs was higher than previous studies on 
the general population, and may be the first to examine veterans specifically. Using different 
blackout periods for OACs based on their pharmacotherapeutic properties would provide a less 
biased comparison of incidence rates and odds of bleeding across categories. Future research 
should focus on uncovering associations that would explain the much higher cumulative 
incidence of bleeding among veterans not prescribed OACs, and the lower incidence rates and 
























Figure 2.1. Comparison of Cumulative Incidence of Gastrointestinal Bleeding, No Blackout 




Figure 2.2. Comparison of Cumulative Incidence of Intracranial Bleeding, No Blackout Period 



















Figure 2.3. Whisker Plot Comparing Incidence Rates per 100 Person-years Over Five Years 
(2011 – 2015) by OAC Category and Bleeding Event Type. 
 
KEY: Red dot = incidence rate per 100 person-years; Blue squares = 95% confidence intervals 
No BO = no blackout period; 5D BO = 5-day blackout period 
GI Bldg = gastrointestinal bleeding; ICR Bldg = intracranial bleeding 
 
 
Table 2.1. Baseline Cohort Characteristics by OAC Prescription Category. 
Variable No OAC DOAC Warfarin p-Value 
Number of Subjects 125,740 1,040 3,970   
Age (mean (sd)) 70.68 (9.86) 75.54 (8.62) 71.76 (8.97) <0.001 
Gender = Male (%) 121,325 (96.5) 1,024 (98.5) 3883 (97.8) <0.001 
Marital Status (%)       <0.001 
   Never Married 16,808 (13.4) 89 (8.6) 486 (12.2)   
   Divorced 26,428 (21) 194 (18.7) 978 (24.6)   
   Married 67,458 (53.6) 618 (59.4) 1,862 (46.9)   
   Separated 5,235 (4.2) 31 (3) 235 (5.9)   
   Unknown/Missing 93 (0.1)  0 (0) 2 (0.1)   
   Widowed 9,718 (7.7) 108 (10.4) 407 (10.3)   
Percent Service-Connected 
Disability (%)       <0.001 
     None 73,866 (58.7) 639 (61.4) 2,271 (57.2)   
     10-30% 15,396 (12.2) 113 (10.9) 393 (9.9)   
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     40-60% 10,673 (8.5) 60 (5.8) 292 (7.4)   
     70-100% 25,805 (20.5) 228 (21.9) 1,014 (25.5)   
Insurance Coverage (%) 105,884 (84.2) 980 (94.2) 3,545 (89.3) <0.001 
Aspirin (%) 12,090 (9.6) 126 (12.1) 844 (21.3) <0.001 
Antiplatelet Medication (%) 7,419 (5.9) 123 (11.8) 499 (12.6) <0.001 
NSAIDS (%) 38,788 (30.8) 254 (24.4) 1,381 (34.8) <0.001 
Exempt from VA Copayment (%)       0.038 
   No   115,249 (91.7) 927 (89.1) 3,655 (92.1)   
   Unknown/Missing   115 (0.1) 1 (0.1) 2 (0.1)   
   Yes 10,376 (8.3) 112 (10.8) 313 (7.9)   
Number of Prescriptions 
(mean (sd)) 3.54 (2.43) 3.92 (2.26) 3.91 (2.75) <0.001 
Race/Ethnicity (%)       <0.001 
   White Non-Hispanic 94,059 (74.8) 857 (82.4) 3,091 (77.9)   
   American Indian or Alaska 
Native 362 (0.3) 5 (0.5) 12 (0.3)   
   Asian 279 (0.2) 2 (0.2) 3 (0.1)   
   Black Non-Hispanic 19,643 (15.6) 93 (8.9) 584 (14.7)   
   Hispanic or Latino 5,929 (4.7) 28 (2.7) 159 (4)   
   Multiple Races 778 (0.6) 9 (0.9) 26 (0.7)   
   Native Hawaiian or Other 
Pacific Islander 408 (0.3) 7 (0.7) 6 (0.2)   
   Unknown/Missing 4,282 (3.4) 39 (3.8) 89 (2.2)   
Smoking Status (%)       <0.001 
   Never Smoked 44,085 (35.1) 490 (47.1) 1,298 (32.7)   
   Current Smoker 25,762 (20.5) 131 (12.6) 748 (18.8)   
   Former Smoker 54,762 (43.6) 414 (39.8) 1,815 (45.7)   
   Unknown/Missing 1,131 (0.9) 5 (0.5) 109 (2.7)   
Diabetes (%) 51,324 (40.8) 498 (47.9) 2,083 (52.5) <0.001 
Congestive Heart Failure (%) 10,952 (8.7) 265 (25.5) 1,288 (32.4) <0.001 
Hypertension (%) 104,341 (83) 973 (93.6) 3,661 (92.2) <0.001 
Atrial Fibrillation (%) 13,952 (11.1) 891 (85.7) 2,547 (64.2) <0.001 
Chronic Kidney Disease (%) 16,433 (13.1) 170 (16.3) 887 (22.3) <0.001 
Liver Disease (%) 16,090 (12.8) 115 (11.1) 590 (14.9) <0.001 
History of Stroke (%) 10,865 (8.6) 157 (15.1) 732 (18.4) <0.001 
Pulmonary Embolism (%) 1,503 (1.2) 81 (7.8) 594 (15) <0.001 
Deep Vein Thrombosis (%) 5,352 (4.3) 146 (14) 1,194 (30.1) <0.001 
Cancer (%) 37,326 (29.7) 353 (33.9) 1,417 (35.7) <0.001 
Peptic Ulcer (%) 5,496 (4.4) 52 (5) 229 (5.8) <0.001 
Esophageal Varices (%) 654 (0.5) 2 (0.2) 27 (0.7) 0.129 
History of Bleeding (%) 45,078 (35.9) 459 (44.1) 2,097 (52.8) <0.001 
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Body Mass Index (BMI) (%)       <0.001 
   Normal (18.5-24.9) 6,977 (5.5) 25 (2.4) 166 (4.2)   
   Obese (>= 30) 18,447 (14.7) 130 (12.5) 789 (19.9)   
   Overweight(25-29.9) 16,780 (13.3) 103 (9.9) 460 (11.6)   
   Underweight (< 18.5) 205 (0.2) 0 (0) 7 (0.2)   
   Unknown/Missing 83,331 (66.3) 782 (75.2) 2,548 (64.2)   
Heart Valve Replacement (%) 2,125 (1.7) 29 (2.8) 262 (6.6) <0.001 
Acute Myocardial Infarction (%) 3,687 (2.9) 60 (5.8) 333 (8.4) <0.001 
Alcohol Abuse (%) 45,078 (35.9) 459 (44.1) 2,097 (52.8) <0.001 
Median Household Income for 









Table 2.2. Event Type and OAC Category by Study Year for All Subjects (n=130,750). 
Event Type 
   OAC Category 2011 2012 2013 2014 2015 Total 
Death 1 0 1 3 36 41 
No OAC 1 0 1 2 35 39 
DOAC 0 0 0 0 0 0 
Warfarin 0 0 0 1 1 2 
End of Study 0 0 0 0 123,459 123,459 
No OAC 0 0 0 0 118,789 118,789 
DOAC 0 0 0 0 1,004 1,004 
Warfarin 0 0 0 0 3,666 3,666 
Gastrointestinal 
Bleeding 1,480 1,283 1,179 1,262 1,256 6,460 
No OAC 1,461 1,250 1,101 1,197 1,153 6,162 
DOAC 0 1 6 5 19 31 
Warfarin 19 32 72 60 84 267 
Intracranial 
Bleeding 160 128 166 141 195 790 
No OAC 158 124 154 131 183 750 
DOAC 0 1 1 2 1 5 
Warfarin 2 3 11 8 11 35 






















Yes Bleeding & 
5-day Blackout Change 
DOAC 1,010 1,004 -6 94 36 -58 
No OAC 118,813 118,828 15 6,637 6,912 275 
Warfarin 3,677 3,668 -9 519 302 -217 
Total 123,500 123,500 0 7,250 7,250 0 
 
 
Table 2.4. Comparison of Incidence Rates per 100 Person-years Over 5 Years (2011-2015), No 
Blackout Period and 5-day Blackout Period, All Subjects (n=130,750). 




















No OAC 6,637 589,841.43 
1.13 




Bleeding 5,928 13,452.50 
1.01 




Bleeding 709 1,759.76 
0.12 
(0.11, 0.13)  750 1,845.47 
0.13 
(0.12, 0.14) 
DOAC 94 5,162.46 
1.82 




Bleeding 79 206.37 
1.53 




Bleeding 15 43.30 
0.29 
(0.17, 0.47)  5 14.14 
0.10 
(0.04, 0.22) 
Warfarin 519 19,192.54 
2.70 




Bleeding 453 1,143.21 
2.36 




Bleeding 66 162.60 
0.34 





Table 2.5. Unadjusted Logistic Regression Model Using No Blackout Period, All Subjects, and 
Stratified by Gender. No OAC prescription was the comparator.  
All Subjects 
(n=130,750) Estimate  Std. Error p-Value Odds Ratio 95% CI lower 95% CI upper 
(Intercept)  -2.885 0.013 0.000 0.056 0.054 0.057 
DOAC 0.510 0.109 0.000 1.666 1.338 2.049 




(n=126,232)             
(Intercept) -2.893 0.013 0.000 0.055 0.054 0.057 
DOAC 0.511 0.110 0.000 1.668 1.336 2.056 
Warfarin 0.936 0.049 0.000 2.550 2.314 2.805 
Females 
(4,518)             
(Intercept) -2.673 0.061 0.000 0.069 0.061 0.078 
DOAC 0.727 0.758 0.338 2.068 0.324 7.449 
Warfarin 0.688 0.327 0.036 1.991 0.992 3.623 
 
 
Table 2.6. Unadjusted Logistic Regression Model Using 5-day Blackout Period, All Subjects, 
and Stratified by Gender. No OAC prescription was the comparator. 
All Subjects 
(n=130,750) Estimate Std. Error p-Value Odds Ratio 95% CI lower 95% CI upper 
   (Intercept)  -2.844 0.012 0.000 0.058 0.057 0.060 
   DOAC     -0.484 0.170 0.004 0.616 0.434 0.847 
   Warfarin   0.347 0.061 0.000 1.415 1.253 1.593 
Males 
(n=126,232)             
   (Intercept) -2.852 0.013 0.000 0.058 0.056 0.059 
   DOAC     -0.520 0.175 0.003 0.595 0.414 0.824 
   Warfarin   0.353 0.062 0.000 1.424 1.259 1.605 
Females 
(n=4,518)             
   (Intercept) -2.659 0.061 0.000 0.070 0.062 0.079 
   DOAC     0.713 0.758 0.347 2.040 0.319 7.345 
   Warfarin   0.223 0.399 0.577 1.249 0.520 2.543 
 
 
Table 2.7. Adjusted Logistic Regression Model, No Blackout Period, All Subjects (n=130,750). 












(Intercept) -5.068 0.158 0.000 0.006 0.005 0.008 
History of Bleeding 4.487 0.084 0.000 88.890 75.969 105.555 
Esophageal Varices 0.543 0.109 0.000 1.720 1.380 2.118 
Male 0.481 0.066 0.000 1.617 1.428 1.847 
History of Stroke 0.432 0.037 0.000 1.540 1.441 1.663 
Ulcer 0.407 0.046 0.000 1.503 1.370 1.640 
Warfarin 0.384 0.058 0.000 1.468 1.308 1.647 
Aspirin 0.298 0.037 0.000 1.347 1.250 1.444 
DOAC 0.263 0.120 0.028 1.300 0.991 1.589 
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Unknown Race/Ethnicity 0.218 0.081 0.008 1.243 1.053 1.448 
Antiplatelet Medication 0.217 0.047 0.000 1.242 1.133 1.363 
Congestive Heart Failure 0.206 0.040 0.000 1.228 1.137 1.327 
Acute Myocardial Infarction 0.178 0.058 0.002 1.195 1.056 1.323 
NSAIDS 0.175 0.027 0.000 1.191 1.128 1.253 
Black Non-Hispanic Race 0.160 0.033 0.000 1.173 1.101 1.254 
Current Smoker 0.106 0.035 0.003 1.112 1.038 1.191 
Cancer 0.070 0.028 0.013 1.073 1.017 1.135 
Number of Prescriptions -0.021 0.007 0.002 0.980 0.967 0.992 
Age -0.026 0.002 0.000 0.974 0.971 0.977 
Married -0.085 0.039 0.029 0.918 0.853 0.993 
Unknown BMI -0.160 0.057 0.005 0.852 0.766 0.958 
 
 
Table 2.8. Adjusted Logistic Regression Model, 5-day Blackout Period, All Subjects 












(Intercept) -5.051 0.158 0.000 0.006 0.005 0.009 
History of Bleeding 4.491 0.084 0.000 89.250 76.034 105.650 
Esophageal Varices 0.536 0.109 0.000 1.709 1.376 2.112 
Male 0.487 0.066 0.000 1.627 1.432 1.854 
History of Stroke 0.433 0.037 0.000 1.541 1.434 1.656 
Ulcer 0.404 0.046 0.000 1.498 1.368 1.639 
Aspirin 0.321 0.037 0.000 1.378 1.282 1.481 
Antiplatelet Medication 0.235 0.047 0.000 1.264 1.152 1.386 
Unknown Race/Ethnicity 0.228 0.081 0.005 1.256 1.068 1.469 
Congestive Heart Failure 0.223 0.040 0.000 1.249 1.156 1.350 
Pulmonary Embolism 0.220 0.081 0.007 1.246 1.061 1.459 
Atrial Fibrillation 0.201 0.039 0.000 1.223 1.133 1.318 
Acute Myocardial Infarction 0.181 0.058 0.002 1.199 1.069 1.341 
NSAIDS 0.181 0.027 0.000 1.198 1.137 1.263 
Black Non-Hispanic Race 0.153 0.033 0.000 1.165 1.092 1.243 
Current Smoker 0.105 0.035 0.003 1.111 1.037 1.190 
Cancer 0.065 0.028 0.020 1.068 1.010 1.128 
Number of Prescriptions -0.020 0.007 0.002 0.980 0.968 0.993 
Age -0.027 0.002 0.000 0.974 0.970 0.977 
Married -0.083 0.039 0.033 0.920 0.853 0.994 
Unknown BMI -0.162 0.057 0.005 0.851 0.761 0.953 
Warfarin -0.329 0.069 0.000 0.720 0.628 0.822 





Bleeding Risk Factors and Time-to-Event Analysis of Older Veterans 
Prescribed Warfarin or Direct Oral Anticoagulants 
 
3.1 Background 
The oral anticoagulant (OAC) warfarin has been used for more than 60 years to help 
reduce the risk of blood clot formation associated with conditions such as atrial fibrillation and 
following acute myocardial infarction, but is associated with an increased risk of bleeding.15 
Previous studies have found that use of warfarin doubled the risk of bleeding over those not 
prescribed an OAC.15 Studies have also found that 3 – 12% of patients prescribed warfarin 
experienced a major bleeding event,17,55 and 2% died following major bleeding.17 A study 
published in 2008 found that in the United States gastrointestinal bleeding accounted for 
approximately 300,000 hospital admissions per year, with an average length of stay of 6.53 days, 
and total costs of $2.5 billion annually.95 
New or Direct OACs (DOACs), were first approved by the FDA in 2010,26 and while 
there are several studies comparing the risk of bleeding between DOACs and 
warfarin,14,27,29,34,86,96–98 there are few studies comparing the risk factors for bleeding between 
DOACs and warfarin among veterans. Identifying risk factors could prevent the morbidity, 
mortality, and cost resulting from bleeding following OAC prescription among veterans. 
The objectives of this study were to identify risk factors for gastrointestinal and 
intracranial bleeding and to calculate the relative risk of bleeding over time through time-to-
event analysis among veterans age 50 to 89 who were prescribed warfarin or DOACs using a 
retrospective cohort design. In undertaking time-to-event analysis, this study sought to replicate 
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previous research by Hippisley-Cox34 in this cohort of older veterans. This study was approved 
by the U.S. Department of Veterans Affairs (VA), Veterans Integrated Service Network- (VISN-
) 2 Institutional Review Board, Research and Development Committee, and Safety Committee.  
3.2 Data and Methods 
3.2.a Participants and Data Source 
Subjects included in the study were veterans age 50 to 89 with a five-digit Zip code and 
at least two primary care visits at a VISN-2 facility between October 1, 2010 and September 30, 
2011, and assigned a primary care provider. The VISN-2 network includes 14 hospitals and 57 
Community Based Outpatient Clinics in New York and New Jersey, and one Community Based 
Outpatient Clinic in Pennsylvania.62 The first OAC prescription on or after October 1, 2010 was 
used as the index date. Time-to-event for bleeding was calculated from the index date to the date 
of the first ICD-9 or ICD-10 code for gastrointestinal or intracranial bleeding (see Appendix 1 
for list) in the subject’s electronic health record. The cohort was followed until September 30, 
2015. The study period was October 1, 2010 through September 30, 2015, for a total of five 
Federal fiscal years – the common reporting cycle for VA. The 5,010 subjects contributed 10,754 
person-years of observation time to the study. Ninety-three percent (n=4,670) of subjects were 
followed until the end of the study. Due to their small numbers, gastrointestinal and intracranial 
bleeding events were grouped together for regression and time-to-event analyses. 
3.2.b Study Variables 
The primary dependent variable was the presence of an ICD-9 or ICD-10 Code for 
gastrointestinal or intracranial bleeding (see Appendix 1), recorded in the dataset as a 
dichotomous variable. Independent variables included a categorical variable for OAC 
prescription (warfarin or DOAC: rivaroxaban, dabigatran, or apixaban). Exposure to an OAC 
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was determined by classifying subjects as having a prescription for an OAC at the time of a 
bleeding event only if the prescription preceded the bleeding event by five or more days, 
resulting in a 5-day blackout period. Subjects included in the cohort did not have a prescription 
for an OAC in the six months prior to their index date. 
Other dichotomous independent variables were: prescriptions for medications associated 
with bleeding34 (aspirin, non-aspirin antiplatelet medications, non-steroidal anti-inflammatory 
drugs (NSAIDS), statins, antidepressants, amiodarone, and antifungals), diagnosis of 
hypertension, chronic kidney disease, liver disease, history of stroke or bleeding (see Appendix 
2), congestive heart failure, diabetes, atrial fibrillation, deep vein thrombosis, cancer, pulmonary 
embolism, non-bleeding peptic ulcer, acute myocardial infarction, alcohol abuse, and heart valve 
replacement. Other dichotomous variables were low platelet count at index and a diagnosis or 
procedure code for heart valve replacement. Demographic variables included age and number of 
prescriptions at index date as continuous variables, and male gender, obese (BMI > 30), married, 
smoker, and white non-Hispanic race/ethnicity as dichotomous variables. Several variables were 
included as proxy measures for socioeconomic status, including insurance coverage, exemption 
from VA copayment (an indicator of low income), and having a service-connected disability 
rating (a documented chronic physical or mental disability attributed to an individual’s military 
service – as an indicator of inability to work) as dichotomous variables. Median household 
income, Townsend score, and percent rural (for county of residence) were included as 
continuous variables. Zip code-level data was obtained through the U.S. Census Bureau 
American Community Survey website,67 and county-level data was obtained from the National 
Center for Health Statistics.65 
3.2.c Townsend Score 
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The Townsend score is a population measure that estimates material deprivation,68 and 
has been used in the U.K. for many years to estimate relative deprivation and measure 
correlations between deprivation and health status.34,69 The Townsend score is an unweighted 
sum of four area-level measures: percent of households with no vehicle, more than one occupant 
per room (overcrowding), dwellings which are renter-occupied, and unemployment.69 The 
Townsend score has been shown to correlate well with health-related measures such as overall 
health, depression, and long-term illness.69 A 2015 study found that median household income 
approximated deprivation as well as the Townsend score did,70 though studies from both the 
U.K. and U.S. have found that the Townsend score may not accurately reflect relative 
deprivation in urban areas.69–72  
3.2.d Analysis Approach 
Analyses were completed using R version 3.2.0. Kaplan-Meier and survival (time-to-
event) curves were generated for the entire cohort, for the subset of subjects with a diagnosis of 
atrial fibrillation, and the subset of subjects age 75 or older. Subgroup analysis for subjects with 
a diagnosis of atrial fibrillation was conducted because several previous studies included only 
subjects with a diagnosis of atrial fibrillation, so this subgroup analysis would allow for direct 
comparison with those studies.14,86,89 Subgroup analysis for subjects age 75 or older was 
conducted because a recent non-veteran population-based study found risk of bleeding higher 
among subjects age 75 or older prescribed DOACs compared to those prescribed warfarin.27 This 
subgroup analysis was intended to confirm or refute this finding in this cohort of older veterans. 
Time-to-event estimates were calculated at < 1, 1-12, 24, 36, 48, and 60 months of study 
for all subjects, subjects with a diagnosis of atrial fibrillation, and subjects age 75 or older. Chi-
square tests were used to calculate statistical significance in time-to-event for bleeding between 
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those with a prescription for warfarin and DOACs. Cox Proportional Hazards regression models 
were developed to identify independent risk factors associated with gastrointestinal or 
intracranial bleeding using the following formula:99 
h(t) = h0(t) X exp(b1x1 + b2x2 + …bnxn) 
 
Where h(t), the hazard function, is a product of the baseline hazard, h0(t), and the exponentiation 
of a sum of coefficients, each of which is a measure of the impact that coefficient had on the 
hazard function.99  
Final models for all subjects, subjects with a diagnosis of atrial fibrillation, and subjects 
age 75 or older were reached by using an iterative process where groups of variables were added 
to the baseline hazard (survival object) and OAC category outcome, starting with demographic 
variables (age, male gender, married, white non-Hispanic race, smoker, and obese), then adding 
medications (aspirin, antiplatelet medications, NSAIDS, steroids, statins, antidepressants, 
amiodarone, antifungals, and the number of prescription medications as index), diagnoses 
(diabetes, congestive heart failure, hypertension, atrial fibrillation, chronic kidney disease, liver 
disease, history of stroke, pulmonary embolism, deep vein thrombosis, cancer, ulcer, acute 
myocardial infarction, history of bleeding, low platelet count at index, and heart valve 
replacement), and socioeconomic variables (disability, insurance coverage, exempt from VA 
copayment, median household income, Townsend score, and percent rural) for a full model. 
Each variable not significant at a p < 0.05 level in the results was removed from the model, until 
a final model was realized with all variables being statistically significant at the p < 0.05 level.  
3.3      Results 
 The cohort consisted of 5,010 subjects. Ninety-eight percent (n=4,907) of the cohort was 
male, 55% (n=2,746) were married, 90% (n=4,525) had some form of insurance coverage, and 
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79% (n=3,948) were White Non-Hispanic. Ninety-three percent (n=4,672) did not experience a 
bleeding event during the study period; 6% (n=298) had a diagnosis of gastrointestinal bleeding, 
and less than 1% (n=40) had a diagnosis of intracranial bleeding. Two subjects died during the 
study period. Eighty percent (n=3,970) of the cohort had an incident prescription for warfarin 
during the study period while 20% (n=1,040) had an incident prescription for a DOAC 
(dabigatran, rivaroxaban, or apixaban). Nineteen percent (n=970) had a new or renewed 
prescription for aspirin, 12% (n=622) for a non-aspirin antiplatelet agent, and 33% (n=1,635) for 
NSAIDS. Eighteen percent of the cohort (n=879) were current smokers. Chronic conditions were 
common: 93% (n=4,634) had a diagnosis of hypertension, 52% (n=2,581) had a diagnosis of 
diabetes, 31% (n=1,553) had a diagnosis of congestive heart failure, 35% (n=1,770) had a 
diagnosis of cancer, 69% (n=3,438) had a diagnosis of atrial fibrillation, and 51% (n=2,556) had 
a diagnosis indicating prior bleeding. Subjects prescribed DOACs were older, whiter, had a 
higher median household income by Zip code, had a higher proportion who were married and 
had insurance, and a lower proportion with a disability or obesity compared to subjects 
prescribed warfarin. Table 3.1 further describes the cohort. 
 Figure 3.1 shows Kaplan-Meier and survival (time-to-event) function curves for all 
subjects, subjects with a diagnosis of atrial fibrillation, and subjects age 75 or older. Tables 3.2, 
3.3, and 3.4 show time-to-event estimates at different points in the study for all subjects, subjects 
with a diagnosis of atrial fibrillation, and subjects age 75 or older by OAC category. The term 
survival in the context of Kaplan-Meier, the survival function, survival estimates, and chi-square 
test results refers to the absence of a bleeding event and not mortality. 
 Only subjects prescribed warfarin experienced bleeding events in the first 30 days 
following OAC prescription; this was true for all subjects, subjects with a diagnosis of atrial 
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fibrillation, and subjects age 75 or older. Time-to-event estimates for bleeding among all subjects 
prescribed DOACs and warfarin were similar for the first eight months following prescription, 
with subjects prescribed DOACs having slightly more time before a bleeding event than those 
prescribed warfarin (0.2 – 0.5% higher). At nine months of study this gap grew slightly, and by 
the end of the study period subjects prescribed DOACs had time-to-event estimates 2.7% higher 
than subjects prescribed warfarin. Among subjects with a diagnosis of atrial fibrillation, those 
prescribed DOACs had slightly better time-to-event estimates starting at 1 month, and continued 
to have estimates 0.6 – 1.3% higher, and 3.4% higher at the end of the study period. Among 
subjects age 75 or older, those prescribed DOACs had slightly better time-to-event estimates for 
the first six months of the study and at 24 and 48 months, ranging from 0.2 – 1.1% higher. For 
months 7 – 12 and 36 months, this difference was reversed, and subjects prescribed warfarin had 
slightly better time-to-event estimates than those prescribed DOACs, with a 1.3% difference at 
month 36. These observed differences were small, and Chi square tests to compare time-to-event 
estimates for bleeding between subjects prescribed DOACs and warfarin were not statistically 
significant when calculated for all subjects (Chisq = 0.9, p = 0.354), for subjects with a diagnosis 
of atrial fibrillation (Chisq = 2, p = 0.154), or for subjects age 75 or older (Chisq = 0, p = 0.938). 
 Tables 3.5, 3.6, and 3.7 show the final Cox Proportional Hazards regression model risk 
factors for all subjects, subjects with a diagnosis of atrial fibrillation, and subjects age 75 or 
older. A prescription for warfarin was protective against gastrointestinal or intracranial bleeding 
in the all subjects final model (HR = 0.341, 95% CI 0.264, 0.440, p = 0.000), but was not a 
statistically significant risk factor in the final models for subjects with a diagnosis of atrial 
fibrillation (HR = 0.881, 95% CI 0.591, 1.314, p = 0.535) or subjects age 75 or older (HR = 




 This study produced four main findings. First, gastrointestinal and intracranial bleeding 
was not common in this cohort of older veterans prescribed OACs (6.79%). Second, only 
subjects prescribed warfarin experienced bleeding in the first 30 days after prescription. This 
finding is consistent with previous studies that found the highest risk of bleeding was in the first 
30 days after warfarin prescription.19,20 Third, subjects age 75 and older prescribed DOACs 
experienced slightly more bleeding than subjects prescribed warfarin at 7 – 12 and 36 months 
after prescription. Even though this finding was not statistically significant, it is suggestive and 
consistent with prior research.27 The average age of subjects in this study prescribed DOACs was 
75.54, while the average age of subjects prescribed warfarin was 71.76.  
 Fourth, this study found that risk factors for gastrointestinal and intracranial bleeding 
varied between all subjects and the subgroups analyzed. This study found that prescriptions for 
antidepressants (HR = 1.35, 95% CI 1.07, 1.70, p=0.012) or statins (HR = 1.31, 95% CI 1.05, 
1.63, p=0.018) were the strongest risk factors for gastrointestinal or intracranial bleeding for all 
subjects, while being married was protective (HR = 0.007, 95% CI 0.003, 0.016, p=0.00). A 
prescription for warfarin was also protective (HR = 0.341, 05% CI 0.26, 0.44, p=0.00), and it is 
unclear why this would be the case, especially considering subgroup analyses on subjects with a 
diagnosis of atrial fibrillation and subjects age 75 or older, which found that a prescription for 
warfarin was not a statistically significant risk factor. Although it should be noted that a 5-day 
blackout period was used to determine OAC exposure, so that could have had an impact on 
results. 
 Subgroup analyses identified history of bleeding as the strongest risk factor for subjects 
with a diagnosis of atrial fibrillation (HR = 37.89, 95% CI 15.56, 92.25, p=0.00) and subjects age 
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75 or older (HR = 21.15, 95% CI 7.93, 56.45, p=0.00). Findings in this study related to risk 
factors are consistent with previous research, but race/ethnicity, smoking status, BMI, lab values, 
other medication classes, and socioeconomic variables (Townsend score, median household 
income, percent service-connected disability, and insurance coverage) were not significant, 
which is not consistent with previous studies.14,27,29,34,86,96–98  
 It is difficult to interpret the results of this study, because few prior studies focus on 
veterans, and the majority of studies on the general population tend to focus on subjects with a 
single diagnosis as an indication for OAC prescription – usually atrial fibrillation or venous 
thromboembolism. Compared to the general population veterans tend to be older, have a higher 
proportion of males, and more chronic diseases.8 Not all eligible veterans seek healthcare 
through the VA system, and those who do may also receive care elsewhere, though VA patients 
in general are less likely to have health insurance.8 It is possible that differences in veterans as a 
population can account for the differences in the results of this study, but why that would be the 
case is a subject for further research. 
 With the availability of more options for oral anticoagulants, patients and providers need 
to have information that allows them to weigh the benefits and risks associated with each. 
Because the first studies comparing warfarin with DOACs relied on clinical trials data, it was 
difficult to translate those findings to patients seen in usual practice, as many clinical trials 
excluded subjects with risk factors for bleeding.96 Three times as many veterans in this study 
were prescribed warfarin (n=3,970) as DOACs (n=1,040). It is important to understand how 
veterans as a population might benefit from increasing the number prescribed DOACs as the 
large number of Vietnam veterans age and have an increased risk of atrial fibrillation and other 
chronic conditions where treatment with an OAC could be indicated, however caution may be 
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warranted when those in need of anticoagulation are age 75 or older or have a history of 
bleeding.  
3.5 Limitations 
 This study had several limitations. Most of the data used in this study came from a 
clinical and administrative database, and did not include private insurance claims or non-VA 
pharmacy benefit data, so services and prescriptions obtained outside the VA healthcare system 
were not included, although every effort was made to include those veterans who appeared to 
receive care at the VA as their primary site of care. The subjects included in this study were from 
New York and New Jersey, and regional differences in demographics may limit the 
generalizability of the findings in this study to the rest of the United States. This study did not 
compare time-to-event for bleeding between warfarin and each DOAC (dabigatran, rivaroxaban, 
and apixaban) separately. The relatively low numbers of DOAC prescriptions, and the very low 
number of outcomes prevented such analyses in this cohort. Also, this study included subjects 
with a variety of diagnoses that are common indications for OAC prescription. In future research 
it may be important to include comparisons of each DOAC with warfarin, and analyze 
subpopulations with specific diagnoses, because some recent studies have found differences in 
outcomes in both of these areas,96,98 though these studies did not focus on veterans.  
 3.6 Conclusion 
 This study compared time-to-event for gastrointestinal and intracranial bleeding for 
veterans prescribed warfarin and DOACs over a five-year period, and identified independent risk 
factors for bleeding. Differences in time-to-event estimates between subjects prescribed warfarin 
and DOACs were small and not statistically significant. The risk factors with the strongest 
association with gastrointestinal or intracranial bleeding was a concurrent prescription for 
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antidepressants for all subjects, and a history of bleeding for subjects with a diagnosis of atrial 



































Figure 3.1. Kaplan-Meier and Survival (time-to-event) Function Curves for All Subjects (a, b), 
Subjects with a Diagnosis of Atrial Fibrillation (c, d), and Subjects Age 75 or Older (e, f), by 
OAC Category. For the purposes of this figure, the term survival refers to the period of time a 

















Table 3.1. Baseline Cohort Characteristics by OAC Prescription Category. 
Variable DOAC Warfarin p-Value 
Number of Subjects 1,040 3,970   
Age (mean (sd)) 75.54 (8.62) 71.76 (8.97) <0.001 
Age >= 75 (%) 552 (53.1) 1,395 (35.1) <0.001 
Male (%) 1,024 (98.5) 3,883 (97.8) 0.231 
Married (%) 649 (62.4) 2,097 (52.8) <0.001 
White Non-Hispanic Race (%) 857 (82.4) 3,091 (77.9) 0.002 
Smoker (%) 131 (12.6) 748 (18.8) <0.001 
Obese (BMI > 30) (%) 130 (12.5) 789 (19.9) <0.001 
Disability (%) 401 (38.6) 1,699 (42.8) 0.015 
Insurance Coverage (%) 980 (94.2) 3,545 (89.3) <0.001 
Exempt from VA Copayment (%) 112 (10.8) 313 (7.9) 0.004 
Median Household Income (mean (sd)) 69,941.75 (26,385.63) 60,797.70 (23,632.76) <0.001 
Townsend score (mean (sd)) 0.56 (0.43) 0.56 (0.42) 0.859 
Percent Rural (mean (sd)) 15.07 (22.50) 21.21 (25.30) <0.001 
Time-to-event (days) (mean (sd)) 381.12 (346.41) 874.75 (527.96) <0.001 
Months of Observation (mean (sd)) 12.72 (11.55) 29.17 (17.61) <0.001 
Censor Type (%)     <0.001 
Death 0 (0.0) 2 ( 0.1)   
End of Study 1,004 (96.5) 3,666 (92.3)   
Gastrointestinal Bleeding 31 (3.0) 267 (6.7)   
Intracranial Bleeding 5 (0.5) 35 (0.9)   
Bleeding Event (Outcome) (%) 36 (3.5) 302 (7.6) <0.001 
Aspirin (%) 126 (12.1) 844 (21.3) <0.001 
Non-aspirin Antiplatelet Medication (%) 123 (11.8) 499 (12.6) 0.553 
NSAIDS (%) 254 (24.4) 1,381 (34.8) <0.001 
Steroids (%) 330 (31.7) 1,890 (47.6) <0.001 
Statins (%) 554 (53.3) 2,257 (56.9) 0.042 
Antidepressants (%) 224 (21.5) 1,111 (28.0) <0.001 
Amiodarone (%) 74 (7.1) 346 (8.7) 0.111 
Antifungal Medication (%) 263 (25.3) 1,378 (34.7) <0.001 
Number of Prescriptions (mean (sd)) 3.92 (2.26) 3.91 (2.75) 0.888 
Diabetes (%) 498 (47.9) 2,083 (52.5) 0.009 
Congestive Heart Failure (%) 265 (25.5) 1,288 (32.4) <0.001 
Hypertension (%) 973 (93.6) 3,661 (92.2) 0.163 
Atrial Fibrillation (%) 891 (85.7) 2,547 (64.2) <0.001 
Chronic Kidney Disease (%) 170 (16.3) 887 (22.3) <0.001 
Liver Disease (%) 115 (11.1) 590 (14.9) 0.002 
History of Stroke (%) 157 (15.1) 732 (18.4) 0.014 
Pulmonary Embolism (%) 81 (7.8) 594 (15.0) <0.001 
61 
 
Deep Vein Thrombosis (%) 146 (14.0) 1,194 (30.1) <0.001 
Cancer (%) 353 (33.9) 1,417 (35.7) 0.31 
Ulcer (%) 52 (5.0) 229 (5.8) 0.377 
Acute Myocardial Infarction (%) 60 (5.8) 333 (8.4) 0.006 
Alcohol Abuse (%) 459 (44.1) 2,097 (52.8) <0.001 
History of Bleeding (%) 459 (44.1) 2,097 (52.8) <0.001 
Low Platelet Count (< 150,000/mcl) (%) 37 (3.6) 88 (2.2) 0.018 




Table 3.2. Time-to-Event Estimates for All Subjects. 
 DOAC Warfarin 
Month At Risk # Events # 
Time-to-Event 
(No Bleeding Event) At Risk # Events # 
Time-to-Event 
(No Bleeding Event) 
< 1 1,040 0 100.00% 3,970 10 99.70% 
1 1,017 8 99.20% 3,937 30 99.00% 
2 951 2 99.00% 3,860 15 98.60% 
3 891 2 98.80% 3,791 11 98.30% 
4 832 3 98.40% 3,709 10 98.10% 
5 771 3 98.00% 3,645 19 97.50% 
6 701 2 97.80% 3,560 7 97.30% 
7 647 1 97.60% 3,479 10 97.10% 
8 597 2 97.30% 3,408 9 96.80% 
9 552 1 97.10% 3,331 10 96.50% 
10 519 1 96.90% 3,269 10 96.20% 
11 484 1 96.70% 3,195 8 96.00% 
12 439 1 96.50% 3,128 8 95.70% 
24 168 6 94.50% 2,336 59 93.70% 
36 77 3 91.80% 1,539 45 91.50% 
48 13 0 91.80% 829 31 89.10% 
60 0 0 NA 70 10 87.40% 
 
 
Table 3.3. Time-to-Event Estimates for Subjects with a Diagnosis of Atrial Fibrillation. 
 DOAC Warfarin 
Month At Risk # Events # 
Time-to-Event 
(No Bleeding Event) At Risk # Events # 
Time-to-Event 
(No Bleeding Event) 
< 1 891 0 100.00% 2,547 8 99.70% 
1 875 4 99.50% 2,525 20 98.90% 
2 825 2 99.30% 2,472 11 98.50% 
3 770 1 99.20% 2,426 7 98.20% 
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4 718 3 98.80% 2,374 6 97.90% 
5 666 2 98.50% 2,331 13 97.40% 
6 604 2 98.10% 2,269 2 97.30% 
7 560 0 98.10% 2,213 7 97.00% 
8 516 2 97.80% 2,166 6 96.70% 
9 476 1 97.50% 2,107 9 96.30% 
10 447 1 97.30% 2,068 5 96.10% 
11 420 1 97.10% 2,017 2 96.00% 
12 385 1 96.80% 1,975 6 95.70% 
24 156 6 94.60% 1,456 42 93.30% 
36 71 3 91.70% 969 32 90.80% 
48 11 0 91.70% 519 21 88.30% 
60 0 0 NA 40 8 86.40% 
 
 
Table 3.4. Time-to-Event Estimates for Subjects Age 75 or Older. 
 DOAC Warfarin 
Month At Risk # Events # 
Time-to-Event 
(No Bleeding Event) At Risk # Events # 
Time-to-Event 
(No Bleeding Event) 
< 1 552 0 100.00% 1,395 3 99.80% 
1 544 2 99.60% 1,383 10 99.10% 
2 510 2 99.20% 1,351 4 98.80% 
3 475 2 98.80% 1,330 6 98.30% 
4 441 1 98.60% 1,308 3 98.10% 
5 408 3 97.90% 1,292 5 97.70% 
6 367 1 97.60% 1,261 1 97.60% 
7 342 1 97.30% 1,225 1 97.60% 
8 318 1 97.00% 1,196 3 97.30% 
9 297 1 96.70% 1,164 1 97.20% 
10 279 0 96.70% 1,148 3 97.00% 
11 263 1 96.30% 1,119 2 96.80% 
12 238 0 96.30% 1,101 3 96.50% 
24 102 1 95.80% 814 18 94.70% 
36 47 3 91.40% 545 14 92.70% 
48 6 0 91.40% 279 9 90.50% 
60 0 0 NA 21 2 89.60% 
 
 
Table 3.5. Cox Proportional Hazards Regression Final Model – All Subjects. 
Variable Hazard Ratio Lower 95% CI Upper 95% CI p-Value 
Warfarin (DOAC was comparator)  0.341 0.264 0.440 0.000 
Married 0.007 0.003 0.016 0.000 
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Statins 1.307 1.048 1.630 0.018 
Antidepressants 1.348 1.068 1.701 0.012 
Antifungals 0.757 0.597 0.961 0.022 
 
 
Table 3.6. Cox Proportional Hazards Regression Final Model – Subjects with a Diagnosis of 
Atrial Fibrillation. 
Variable Hazard Ratio Lower 95% CI Upper 95% CI p-Value 
Warfarin (DOAC was comparator) 0.881 0.591 1.314 0.535 
Age 0.976 0.960 0.991 0.002 
Aspirin 1.650 1.237 2.201 0.001 
Congestive Heart Failure 1.349 1.039 1.753 0.025 
Chronic Kidney Disease 1.352 1.031 1.774 0.030 
Stroke 1.490 1.122 1.979 0.006 
Ulcer 2.080 1.408 3.073 0.000 
Acute Myocardial Infarction 1.854 1.341 2.565 0.000 
History of Bleeding 37.888 15.562 92.246 0.000 
 
 
Table 3.7. Cox Proportional Hazards Regression Final Model – Subjects Age 75 or Older. 
Variable Hazard Ratio Lower 95% CI Upper 95% CI p-Value 
Warfarin (DOAC was comparator) 0.654 0.389 1.099 0.109 
Male Gender 0.337 0.115 0.993 0.049 
Aspirin 1.674 1.036 2.705 0.036 
Steroids 1.549 1.036 2.314 0.033 
Antidepressants 1.634 1.046 2.553 0.031 
Ulcer 1.841 1.001 3.384 0.050 













Predicting Bleeding Risk in Older Veterans Prescribed Warfarin or Direct Oral 




Oral anticoagulants (OACs) are effective in reducing the risk of blood clot formation, a 
complication associated with stroke and deep vein thrombosis, but OACs are associated with an 
increased risk of bleeding.15,100 Several clinical algorithms have been developed to help predict 
who among those prescribed OACs is at highest risk of bleeding.20,24,33,34,100 These algorithms 
were developed so providers could assess a handful of risk factors during a patient visit, and 
using the algorithm name as a mnemonic device (HAS-BLED, ORBIT, ATRIA), calculate a risk 
score for the patient. While it is possible to use computer programs to automate calculation of 
these scores and generate scores for patient populations, this has not been a regular practice of 
healthcare organizations. Reducing harm to patients taking anticoagulants has been a Joint 
Commission Patient Safety Goal (PSG) for hospitals, ambulatory care, and long-term care since 
2008.36 Performance elements associated with this goal include baseline INR testing, following 
evidence-based guidelines, and having and following written facility policies and guidelines 
related to anticoagulant management.37 A randomized controlled trial from Canada published 
five years prior to the PSG found patients taking OACs managed by anticoagulation clinics had 
an INR Therapeutic Time in Range (TTIR) of 82% versus 76% for those patients managed by 
family medicine doctors.38 Despite these and similar findings in other studies, many patients 
taking anticoagulants are not managed in specialized clinics.39  
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In July 2015 the Veteran’s Health Administration (VHA) published a new policy on 
anticoagulation therapy management.40 This policy requires providers with patients on 
anticoagulant therapy to perform periodic risk assessments of these patients, including assessing 
bleeding risk and calculating TTIR.40 Although efforts are underway to enable calculation of 
TTIR across the VHA for patients prescribed OACs, a method or model for predicting bleeding 
risk has yet to be developed. This study will help VHA facilities comply with this policy, and 
also help non-VHA facilities comply with similar local policies and The Joint Commission 
Patient Safety Goal.  
The objectives of this study were to develop and compare models to predict 
gastrointestinal and intracranial bleeding among veterans age 50 to 89 who were prescribed 
warfarin or Direct OACs (DOACs) using a retrospective cohort design. This study was approved 
by the U.S. Department of Veterans Affairs (VA), Veterans Integrated Service Network- (VISN-
) 2 Institutional Review Board, Research and Development Committee, and Safety Committee.  
4.2 Data and Methods 
4.2.a Participants and Data Source 
Subjects included in the study were veterans age 50 to 89 with a five-digit Zip code and 
at least two primary care visits at a VISN-2 facility between October 1, 2010 and September 30, 
2011, and assigned a primary care provider. The VISN-2 network includes 14 hospitals and 57 
Community Based Outpatient Clinics in New York and New Jersey, and one Community Based 
Outpatient Clinic in Pennsylvania.62 The first OAC prescription on or after October 1, 2010 was 
used as the index date. Subjects were considered to have had a bleeding event if an ICD-9 or 
ICD-10 code for bleeding (see Appendix 1 for list) was present in the subject’s electronic health 
record after the index date.  Exposure to an OAC was determined by classifying subjects as 
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having a prescription for an OAC at the time of a bleeding event only if the prescription 
preceded the bleeding event by five or more days, resulting in a 5-day blackout period. Only 
subjects who did not have a prescription for any OAC for at least 180 days prior to their index 
date were included in the cohort. The cohort was comprised of 5,010 subjects and was followed 
until September 30, 2015. The study period was October 1, 2010 through September 30, 2015, 
for a total of five Federal fiscal years – the common reporting cycle for VA. The 5,010 subjects 
contributed 10,754 person-years of observation time to the study. Ninety-three percent (n=4,670) 
of subjects were followed until the end of the study. Due to their small numbers, gastrointestinal 
and intracranial bleeding events were grouped together for analyses. 
Clinical and administrative data were obtained by querying the VA corporate data 
warehouse, the repository for VA electronic health record data. Each subject’s Zip code of 
residence was matched to U.S. Census Bureau American Community Survey (ACS) data, which 
allowed for the inclusion of several Zip code-level variables (described below). In addition, each 
subject’s county of residence was matched to the National Center for Health Statistics (NCHS) 
Urban-Rural Classification Scheme for Counties, which allowed the inclusion of a variable to 
examine the relationship between urbanization and risk of bleeding.65  
4.2.b Study Variables 
In order to accommodate multiple methods and models run from the same dataset, all 
variables were coded as binary (1 or 0). The primary dependent variable was the presence of an 
ICD-9 or ICD-10 Code for gastrointestinal or intracranial bleeding (see Appendix 1). The 
primary independent variable was a prescription for warfarin (versus a DOAC – dabigatran, 
rivaroxaban, or apixaban). Other binary explanatory variables included married; service-
connected disability (any disability rating from the VA); prescription for aspirin, non-aspirin 
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antiplatelet medications, nonsteroidal anti-inflammatory drugs (NSAIDS), steroids, statins, 
antidepressants, carbamazepine, phenytoin, or antifungals; white non-Hispanic race; current 
smoker; diagnosis of diabetes, congestive heart failure, hypertension, atrial fibrillation, chronic 
kidney disease, liver disease, chronic pancreatitis, stroke, deep vein thrombosis, cancer, 
esophageal varices, a history of bleeding (see Appendix 2), alcohol abuse; obese (body mass 
index >= 30); low platelet count (< 150,000/mcl); and male gender. Continuous variables 
included age, percent rural by county (according to NCHS),65 months of observation time 
contributed to the study, count of total outpatient prescriptions at index, Townsend score, and 
median household income by Zip code. Zip code-level data (median household income and 
components of the Townsend score) were obtained from the U.S. Census Bureau American 
Community Survey website.67 Townsend score, a measure of socioeconomic deprivation, is 
described in detail elsewhere.34,68 
4.2.c Analysis Approach 
Analyses were completed using R version 3.4.1. The dataset was randomly split in half, 
resulting in 2,505 subjects in the training dataset, and 2,505 subjects in the validation dataset. Six 
techniques were used to build models to predict gastrointestinal or intracranial bleeding: (1) 
ATRIA,20 ORBIT,33 and HAS-BLED24 scores were calculated then added to the analysis dataset 
as continuous numeric variables. Logistic regression was used to calculate the risk of bleeding 
using these three traditional algorithms, with the corresponding score as the single predictor in 
each model. Logistic regression using an algorithm to choose subsets of the strongest predictors 
from all available variables was employed to choose models with the best 1, 3, 5, and 10 
variables. (2) Time-to-event analysis was used to evaluate the QBLEED algorithm and included 
only those variables used in the published validation study.34 Machine learning algorithms 
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employed included: (3) Least absolute shrinkage and selection operator (lasso) and (4) elastic net 
– two penalized logistic regression variants, and (5) Adaboost and (6) Classification and 
Regression Trees (CART) – two decision tree-based algorithms. Models were trained using the 
training dataset and then evaluated using the validation dataset. 
4.2.d Method for Evaluating Predictive Models 
Models run against the validation dataset were evaluated according to five unweighted 
measures, using criteria from previous research and texts: (1) classification error, (2) calibration, 
(3) sensitivity, (4) positive predictive value, and (5) area under the receiver operating curve .31,47 
Table 4.1 shows the measures, definitions, and evaluation criteria. A score for each model was 
constructed using the following scheme: the best performing model for each measure was 
awarded three points, the second best model two points, and the third best model one point. 
Points for each measure were added together for a total model score. Evaluation measures for all 
models will be shown, and then the two best models will be discussed in more detail. 
Gains tables were produced for the two best models to evaluate how well they were able 
to correctly classify subjects,47 and to aid decision making in terms of whether or not an 
intervention based on one of the models would be feasible and likely to have the desired impact. 
For example, in the context of the current study, if the VA wanted to develop an intervention 
targeting veterans who were prescribed OACs and identified as being at high risk for subsequent 
bleeding, it would be valuable to know at what risk level the intervention should be triggered, as 
well as the anticipated number of veterans who would likely meet this risk threshold, and how 
many veterans could be expected to actually have a bleeding event at the set threshold level. 
Gains show how the predictions made by the model are better than chance (i.e. what is gained by 
using the model), and are evaluated using the measures accuracy, sensitivity, and positive 
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predictive value (PPV).47,101 Accuracy is defined as 1 – error rate, while PPV is defined as the 
proportion of events predicted by the model that are correct, and sensitivity is defined as the 
proportion of true events predicted by the model.101 Gains tables for the ORBIT and logistic 
regression with subset of 5 best variables models are shown in Tables A.3.1 and A.3.2 of 
Appendix 3. 
Predicted probabilities were plotted for the two best models to visually depict how 
subjects were grouped according to predicted risk. Lift charts were generated to visually 
illustrate the gain derived from the model. The Area Under the Curve (AUC) is a statistical 
measure used to assess how well a model predicts whether subjects will experience a specified 
outcome.30 
4.3      Results 
 The cohort was comprised of 5,010 subjects. Ninety-eight percent (n=4,907) of the cohort 
was male, 55% (n=2,746) were married, and 79% (n=3,948) were White Non-Hispanic race. 
Ninety-three percent (n=4,672) did not experience a bleeding event during the study period; 6% 
(n=298) had a diagnosis of gastrointestinal bleeding, and less than 1% (n=40) had a diagnosis of 
intracranial bleeding. Eighty percent (n=3,970) of the cohort had an incident prescription for 
warfarin during the study period while 20% (n=1,040) had an incident prescription for a DOAC. 
Nineteen percent (n=970) had a new or renewed prescription for aspirin, 12% (n=622) for a non-
aspirin antiplatelet medication, and 33% (n=1,635) for NSAIDS. Thirty-eight percent (n=1,902) 
of the cohort had never smoked, 44% (n=2,229) were former smokers, and 18% (n=879) were 
current smokers. Chronic conditions were common: 93% (n=4,634) had a diagnosis of 
hypertension, 52% (n=2,581) had a diagnosis of diabetes, 31% (n=1,553) had a diagnosis of 
congestive heart failure, 35% (n=1,770) had a diagnosis of cancer, 69% (n=3,438) had a 
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diagnosis of atrial fibrillation, and 51% (n=2,556) had a diagnosis indicating prior bleeding. 
Table 4.2 further describes the cohort. 
 Model performance varied greatly. No single model performed the best on every 
evaluation measure. Two models had scores in the top three for three evaluation measures: the 
ORBIT algorithm and logistic regression with 5 variable subset. Three models (logistic 
regression 10 variable subset, elastic net, and Adaboost) did not have any evaluation measures in 
the top three in terms of performance. Table 4.3 shows the models, variables, and results. 
 Overall, the ORBIT algorithm performed the best with a score of 7 with the lowest error, 
highest PPV, and third highest sensitivity. Logistic regression with 5 variable subset had a score 
of 5 with the second highest PPV and AUC and third lowest error. The ATRIA algorithm had a 
score of 4 and tied for second lowest error and had the second best calibration. Two machine 
learning algorithms had scores in the top three for two evaluation measures. The lasso algorithm 
had the third best calibration and third highest AUC. The CART algorithm had the second 
highest sensitivity and third highest PPV. All models had poor sensitivity. Half of the models 
had excellent calibration. Two-thirds of the models had a PPV of zero; despite this seven of 12 
models had an AUC between 0.80 and 0.89.  
 Using logistic regression the ORBIT score had an odds ratio of 2.15 (95% confidence 
interval 1.88, 2.48). As shown in table 4.3, bleeding history was the single best predictor for a 
bleeding event in the study population. Table 4.4 shows the odds ratios and confidence intervals 
for the logistic regression model with subset of best 5 variables, and illustrates how strong the 
association between bleeding history and subsequent bleeding event is compared to the other top 
five predictors. Bleeding history is a component of the ORBIT score.33 
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 Tables 1 and 2 of Appendix 3 show gains tables for both the ORBIT model and the 
logistic regression model with subset of best 5 variables. The gains tables show that using the 
ORBIT model an intervention could be developed for any patient with a risk score of 0.21 or 
greater, which was approximately 10% (n=235) of the study population included in the 
validation dataset. At this threshold the model would accurately predict bleeding 93% of the 
time, with a sensitivity of 11% and a PPV of 46%. Using the subset of five best variables model, 
a threshold of 0.30 or greater would include approximately 10% (n=259) of the study population 
included in the validation dataset and accurately predict bleeding 92% of the time with a 
sensitivity of 24% and a PPV of 37%. At a threshold of 0.21 the sensitivity for the ORBIT model 
is lower than for the subset of five best variables at a threshold of 0.30 (11% versus 24%, 
respectively), however the ORBIT model has higher PPV at 46% versus 37%, respectively. 
 Figure 4.1 shows predicted probability plots and lift charts for the ORBIT and the logistic 
regression with subset of best five variables models. The predicted probability plots illustrate the 
findings from the gains tables: that most subjects are classified as low risk. This is not entirely 
surprising since the outcome is rare – only 7% of subjects experienced a bleeding event. The lift 
chart for the ORBIT model shows how the model predicts bleeding events above the level of the 
mean response for approximately the first 30% of subjects in the validation dataset, and then the 
model does no better in predicting bleeding events than using the mean response as a predictor. 
The lift chart for the logistic regression model with subset of best five variables shows that the 
model predicts bleeding events better than using the mean response for approximately the first 
20% of subjects in the validation dataset, and then it does no better, and in some cases does 
worse than using the mean response as a predictor. 
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 The lasso algorithm selected the same five variables as logistic regression with the best 
subset algorithm. Table 3 in Appendix 3 shows the variables selected by the lasso model and 
their corresponding odds ratios. As with the logistic regression models, the lasso model found 
bleeding history to be the strongest predictor. 
 Figure 1 in Appendix 3 shows the decision tree for the CART machine learning 
algorithm. Again, bleeding history was the top predictor, followed by months of observation, 
warfarin prescription, and congestive heart failure. Interestingly, the decision tree included other 
variables – such as age, percent rural, median household income, marital status, and NSAIDS 
prescription – that were not significant predictors in the other models. 
4.4 Discussion 
 The main finding of this study was that a predictive model based on the ORBIT score33 
performed better than several other traditional and machine learning algorithms, with an AUC of 
0.75. A logistic regression model with a subset of 5 best variables algorithm performed second 
best, and had an AUC of 0.85. Two machine learning algorithms also performed fairly well in 
predicting bleeding risk: a lasso model with an AUC of 0.85, and a CART model with an AUC 
of 0.82. Overall model performance was based on five different performance measures; many 
studies evaluated predictive model performance using only AUC. No single model scored best in 
the five measures used to evaluate them. Even in the case of the two best models the 
performance based on the set of five measures chosen was not strong. Models could have been 
evaluated differently by weighting the measures or choosing different measures. 
Atrial fibrillation patients are commonly prescribed OACs, making them a well-studied 
patient population, and the source for the traditional bleeding risk algorithms used as 
comparators for this study. Although developed using atrial fibrillation patients, these algorithms 
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have been used to predict bleeding risk among patients other than those diagnosed with atrial 
fibrillation. The oldest of the traditional algorithms evaluated in this study was HAS-BLED.24 A 
study comparing HAS-BLED to other bleeding risk prediction schemes found HAS-BLED had a 
higher AUC (ranging from 0.60-0.66) than the four other algorithms to which it was compared.32 
The original study describing HAS-BLED as a convenient and effective predictor of bleeding 
risk found an AUC range of 0.72-0.91.24 The HAS-BLED algorithm is recommended as the 
preferred method for determining bleeding risk according to the European Society of 
Cardiology34 and the American College of Cardiology,35 and could be considered the “gold 
standard” in terms of bleeding risk prediction algorithms. The ATRIA algorithm was originally 
developed to predict stroke risk in patients with atrial fibrillation,20 but it has been used to predict 
bleeding risk as well.33 A study comparing ATRIA to an older algorithm (CHADS2) found that 
ATRIA had an AUC of 0.73 while the older algorithm had an AUC of 0.70.20  A recent study 
comparing a new bleeding risk algorithm, ORBIT, to HAS-BLED and ATRIA, found ORBIT 
had an AUC of 0.67, compared to 0.64 for HAS-BLED and 0.66 for ATRIA.33 This study used a 
completely different population for validating their risk models, and found the AUCs decreased 
by approximately 0.05 for each of the three models during validation.33 The QBLEED score, 
based on a study done in the U.K., found Townsend score was a predictor for bleeding risk.34 
QBLEED is a survival model, and incorporates many of the HAS-BLED risk factors.34 The 
QBLEED validation study found an AUC of 0.77 for women and 0.75 for men, but did not 
directly compare results with HAS-BLED or ATRIA.34 
The ability to use published algorithms to assign risk can save healthcare organizations 
many hours of work in developing their own, which many facilities may not have the capability 
to do. Historically the biggest shortcoming of using HAS-BLED, ORBIT, or ATRIA was that 
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those algorithms were meant to be calculated manually, one patient at a time at the point of care, 
and being calculated in this way they did not give healthcare providers insight into patient 
populations. Using automated tools, the ORBIT score and bleeding risk could be calculated at 
the point of care, and the bleeding risk of one patient could be compared to others with similar 
demographics, comorbidities, and medications. The variables included in ORBIT are readily 
available in electronic health records. 
This study compared HAS-BLED, ATRIA, ORBIT, and QBLEED to logistic regression 
and machine learning predictive models and found a model using the ORBIT score performed 
best, and with a higher AUC than that found in previously published studies. The ORBIT score 
includes reduced hemoglobin, hematocrit, or history of anemia, history of bleeding, insufficient 
kidney function, treatment with an antiplatelet agent, and age greater than or equal to 75.33 Since 
history of bleeding was the strongest predictor of bleeding in this study population it is easy to 
see how ORBIT, logistic regression with 5 best variables, lasso, and CART all performed well. 
The ORBIT and logistic regression with subset of 5 best variables models are simple and easy to 
interpret, and can be used to predict risk among veterans using data readily available in  the 
electronic health record. 
4.5 Limitations 
 This study had several limitations. Data used in this study came from a VA clinical and 
administrative database, and did not include non-VA claims or pharmacy benefit data, so 
services and prescriptions obtained outside the VA healthcare system were not included, 
although every effort was made to include veterans who appeared to receive care at the VA as 
their primary site of care. The subjects included in this study were primarily from New York and 
New Jersey, and regional differences in demographics may limit the generalizability of findings 
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to the rest of the United States or other countries. This study utilized minimal preprocessing of 
data prior to predictive modeling, although some feature engineering was performed in order to 
make all variables binary. It is possible that the use of categorical variables might change the 
outcome of different models, as might more preprocessing, or other model tuning techniques 
such as cross-validation, boosting, and bagging. Due to the rare outcome, data was split 50/50 for 
training and validation, in order to distribute the outcome more evenly for model learning. It is 
possible that different data splits might change the results of the models. Machine learning tools 
perform better with larger datasets,44 and the datasets in this study totaled 2,505 subjects each 
(training and validation), which is adequate for machine learning algorithms and statistical 
inference, but machine learning algorithms improve with increasing amounts of data so it is 
possible the machine learning algorithms used in this study would have performed better with 
larger datasets. This study focused heavily on logistic regression and machine learning variants 
of logistic regression, and it is possible that other machine learning algorithms for classification, 
such as support vector machine, k-nearest neighbors, or discriminant analysis would have 
performed differently or better. Predictive models used in this study were evaluated according to 
five unweighted measures. It is possible that models could have scored differently if weighting 
of measures was applied, or if different measures were selected. The model evaluation rubric for 
this study resulted in the selection of models that favored specificity (identification of true 
negatives) over sensitivity (identification of true positives). While this might be appropriate for 
some uses, it is not preferable from a clinical point of view, where it would be better to favor 
measures and models that include more false positives, because it would be better to intervene 
with more patients who turned out to be false positives than to miss them with a model that 
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focused on true negatives and intervene with more false negative patients and miss some who 
were true positives.  
 4.6 Conclusion 
 This study compared models to predict bleeding risk among older veterans prescribed 
warfarin and DOACs. Using logistic regression the ORBIT model performed the best. Logistic 
regression with a subset of best 5 variables performed second best. Lasso and CART machine 
learning algorithms also performed well, although no single model performed strongly in all 
measures that were evaluated. This study highlights the importance of comparing modeling 
techniques, as a simpler, more easily interpretable model may perform as well as a more 
sophisticated one. Accurately predicting gastrointestinal and intracranial bleeding among older 
veterans prescribed OACs is possible, and identifying those at highest risk of bleeding following 
OAC prescription can be done easily using a few clinical variables from the electronic health 
record. Because history of bleeding is such a strong predictive factor, it may be possible to 
design an intervention around that single risk factor without the use of a predictive model, and 


















Figure 4.1. Predicted Probability Plots and Lift Charts for the ORBIT Predictive Model and the 




Table 4.1. Predictive Model Evaluation Measures, Definitions, and Criteria. 
Measure Definition Evaluation Criteria 
Classification Error Percent of incorrect predictions31,47 Lower is better 
Calibration The mean absolute difference 
between predicted probability and 
observed proportion31 
0 – 4% = excellent 
5 – 9% = very good 
10 – 14% = good 
15 – 20% = fair 
> 20% = poor 
Sensitivity The probability that bleeding event 
is predicted correctly for subjects 
who had a bleeding event47 
 
< 0.6 = poor 
 
0.6 – 0.69 = fair 
 
0.7 – 0.79 = good 
 
0.8 – 0.89 = very good 
 
0.9 – 1.0 = excellent 
Positive Predictive Value The probability of having a bleeding 
event when classified as having a 
bleeding event47 
Area Under the Receiver 
Operating Curve 
The overall ability of a model to 
correctly classify subjects who do 








Table 4.2. Baseline Cohort Characteristics by OAC Prescription Category. 
Variable DOAC Warfarin 
p-
Value 
Number of Subjects 1,040 3,970   
Age (mean (sd)) 75.54 (8.62) 71.76 (8.97) <0.001 
Married (%) 649 (62.4) 2,097 ( 52.8) <0.001 
Male Gender (%) 1,024 (98.5) 3,883 (97.8) 0.231 
Service-Connected Disability (%) 401 (38.6) 1,699 ( 42.8) 0.015 
Percent Rural (mean (sd)) 15.07 (22.50) 21.21 (25.30) <0.001 
Months to Bleeding Event (mean (sd)) 12.72 (11.55) 29.17 (17.61) <0.001 
Aspirin (%) 126 (12.1) 844 ( 21.3) <0.001 
Non-aspirin Antiplatelet Medication (%) 123 (11.8) 499 ( 12.6) 0.553 
NSAIDS (%) 254 (24.4) 1,381 ( 34.8) <0.001 
Steroids (%) 330 (31.7) 1,890 ( 47.6) <0.001 
Statins (%) 554 (53.3) 2,257 ( 56.9) 0.042 
Antidepressants (%) 224 (21.5) 1,111 ( 28.0) <0.001 
Carbamazepine (%) 3 ( 0.3) 19 (  0.5) 0.574 
Phenytoin (%) 1 ( 0.1) 10 (  0.3) 0.56 
Antifungals (%) 263 (25.3) 1,378 ( 34.7) <0.001 
Number of Prescriptions (mean (sd)) 3.92 (2.26) 3.91 (2.75) 0.888 
White Non-Hispanic Race (%) 857 (82.4) 3,091 ( 77.9) 0.002 
Smoker (%) 131 (12.6) 748 ( 18.8) <0.001 
Diabetes (%) 498 (47.9) 2,083 ( 52.5) 0.009 
Congestive Heart Failure (%) 265 (25.5) 1,288 ( 32.4) <0.001 
Hypertension (%) 973 (93.6) 3,661 ( 92.2) 0.163 
Atrial Fibrillation (%) 891 (85.7) 2,547 ( 64.2) <0.001 
Chronic Kidney Disease (%) 170 (16.3) 887 ( 22.3) <0.001 
Liver Disease (%) 115 (11.1) 590 ( 14.9) 0.002 
Chronic Pancreatitis (%) 4 ( 0.4) 94 (  2.4) <0.001 
Stroke (%) 157 (15.1) 732 ( 18.4) 0.014 
Deep Vein Thrombosis (%) 146 (14.0) 1,194 ( 30.1) <0.001 
Cancer (%) 353 (33.9) 1,417 ( 35.7) 0.31 
Esophageal Varices (%) 2 ( 0.2) 27 (  0.7) 0.106 
Bleeding History (%) 459 (44.1) 2,097 ( 52.8) <0.001 
Alcohol Abuse (%) 459 (44.1) 2,097 ( 52.8) <0.001 
Obese (BMI >= 30) (%) 130 (12.5) 789 ( 19.9) <0.001 
Low Platelets (< 150,000 mcl) (%) 37 ( 3.6) 88 (  2.2) 0.018 
Townsend Score (mean (sd)) 0.56 (0.43) 0.56 (0.42) 0.859 






HAS-BLED Score (mean (sd)) 4.14 (1.32) 4.25 (1.44) 0.033 
ORBIT Score (mean (sd)) 1.71 (1.25) 1.78 (1.34) 0.173 
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ATRIA Score (mean (sd)) 6.18 (2.20) 5.81 (2.60) <0.001 
Bleeding Event (%) 36 ( 3.5) 302 (  7.6) <0.001 
 
















Regression (1) 3 6.75 0.06 0.00 0.00 0.7480 Bleeding History 
Logistic 
Regression (3) 3 6.75 0.94 0.00 0.00 0.8540 
Bleeding History, Months, 
Warfarin 
Logistic 
Regression (5) 5 6.71 7.55 1.78 60.00 0.8514 
Bleeding History, Months, 
Warfarin, Stroke, CHF  
Logistic 
Regression (10) 0 7.03 16.70 2.37 26.67 0.8467 
Bleeding History, Months, 
Warfarin, Stroke, CHF, CKD, 
Count Meds, Disability, White 
Race, Low Platelets 
ATRIA (1) 4 6.67 0.11 0.00 0.00 0.5551 
Age > 65, Congestive Heart 
Failure, Diabetes, Female 
Gender, History of stroke, 
Hypertension, Liver or renal 
disease 
ORBIT (1) 7 6.47 12.48 4.19 77.78 0.7453 
Age > 75, Anemia, Non-aspirin 
antiplatelet medication, History 
of bleeding, Liver or renal 
disease 
HAS-BLED (1) 2 6.67 3.74 0.00 0.00 0.7323 
Age > 65, Alcohol use/abuse, 
Drug use/abuse, History of 
bleeding, History of stroke, 
Hypertension, Liver or renal 
disease, TTIR < 60% 
QBLEED (22) 3 43.95 40.70 56.21 8.47 0.5764 
Age, Alcohol use/abuse, 
Antidepressants, Non-aspirin 
antiplatelet medication, Atrial 
fibrillation, Cancer, 
Carbamazepine or Phenytoin 
prescription, CHF, Steroids, 
Ethnicity, History of Bleeding, 
Hypertension, Liver or renal 
disease, Low platelet count, 





Lasso (5) 2 6.75 0.36 0.00 0.00 0.8481 
Bleeding History, Months, 
Warfarin, Stroke, CHF  
Elastic Net (34) 0 6.75 3.23 0.00 0.00 0.8274 All 
Adaboost (34) 0 6.79 13.78 0.00 0.00 0.8273 All 











Table 4.4. Odds Ratios and Confidence Intervals for Logistic Regression Model with Subset of 








Stroke    1.77 1.20 2.57 
Bleeding 
History 41.11 17.25 134.25 
Months      0.94 0.93 0.96 
Warfarin   5.87 3.38 10.97 
































5.1 Overview of the Dissertation 
 The three retrospective cohort studies conducted for this dissertation were designed to 
explore the relationship between OAC prescription and gastrointestinal or intracranial bleeding 
among older veterans. Using electronic health record data from the Veterans Health 
Administration combined with American Community Survey and National Center for Health 
Statistics data, a cohort of 130,750 Veterans age 50 to 89 were followed from October 1, 2010 
until September 30, 2015 to compare cumulative incidence, incidence rates, and odds of 
gastrointestinal and intracranial bleeding between veterans prescribed no OACs, warfarin, and 
DOACs (dabigatran, rivaroxaban, or apixaban) (Chapter 2). A subset of 5,010 subjects from the 
cohort with a prescription for warfarin or DOACs was further analyzed to identify risk factors 
and determine the relationship between OAC prescription and bleeding events over time using 
time-to-event analysis (Chapter 3). Predictive models were then developed using traditional and 
machine learning methods for the subset of 5,010 subjects with a prescription for warfarin or 
DOACs to discover a model for predicting risk of gastrointestinal or intracranial bleeding that 
could be easily replicated by either VA or non-VA healthcare facilities (Chapter 4). This final 
chapter of the dissertation will synthesize and summarize the findings from the three studies 
presented in Chapters 2, 3, and 4, discuss the public health and policy impacts of the findings 
from these three studies, and make recommendations for future research. 
5.2 Summary of Findings 
5.2.a Chapter 2 – Incidence and Odds of Gastrointestinal and Intracranial Bleeding 
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 The objectives of the study presented in Chapter 2 were to describe and compare the 
cumulative incidence, incidence rate, and odds of gastrointestinal and intracranial bleeding in 
veterans age 50 to 89 who were prescribed warfarin, DOACs, or no OACs. Two analysis 
approaches were employed: (1) a 5-day blackout period between OAC prescription date and 
counting a bleeding event toward the outcome, and (2) no blackout period, meaning a bleeding 
event at any time after OAC prescription would count as an outcome. 
 This study found that veterans who were not prescribed OACs experienced an average of 
9 to 10 times the number of gastrointestinal bleeding events, and an average of 7 to 8 times the 
number of intracranial bleeding events as would be expected in the general population. Using 
both the no blackout and 5-day blackout period approaches this study found lower incidence 
rates per 100 person-years for gastrointestinal and intracranial bleeding among veterans 
prescribed OACs than previous studies on both veterans and non-veterans.14,27,56 This study also 
found lower odds of bleeding among veterans prescribed an OAC than previous studies;9 this 
was the case regardless of approach. 
 An important finding of the study presented in Chapter 2 was the difference in results 
between the no blackout and the 5-day blackout period approaches. A better approach may be a 
hybrid of the two compared here: to use no blackout period for subjects prescribed DOACs, and 
a 5-day blackout period for subjects prescribed warfarin. Approached in this way, the findings 
suggest subjects prescribed DOACs had comparable rates per 100 person-years for both 
gastrointestinal and intracranial bleeding to subjects prescribed warfarin using a 5-day blackout 
period. 
 Overall the findings of the study presented in Chapter 2 suggest that the approach used to 
determine when a bleeding event should count as an outcome following OAC prescription will 
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have a statistically significant effect on findings. There is no established body of research that 
helps to explain the high cumulative incidence of gastrointestinal and intracranial bleeding 
among veterans not prescribed OACs. One possible explanation is the increased number of 
chronic conditions found in the veteran population. Another could be the use of blood thinning 
medications prescribed outside the VA system or over-the-counter medication use (such as 
aspirin) not captured in the VA EHR. 
 Both hypotheses associated with the aim of this study were disproved: 
(1) Hypothesis – cumulative incidence and incidence rates of gastrointestinal and 
intracranial bleeding will be comparable to previous studies. 
a. Finding – cumulative incidence among subjects not prescribed OACs 
was higher, and incidence rates were lower among subjects prescribed 
warfarin or DOACs in this cohort than in previous studies. 
(2) Hypothesis – cumulative incidence and incidence rates of gastrointestinal and 
intracranial bleeding will be higher among subjects prescribed DOACs 
compared to those prescribed warfarin. 
a. Finding – cumulative incidence and incidence rates of gastrointestinal 
and intracranial bleeding were higher among subjects prescribed 
warfarin than those prescribed DOACs using both approaches. A 
hybrid approach suggests incidence would be comparable between 
warfarin and DOACs.  
5.2.b Chapter 3 – Bleeding Risk Factors and Time-to-Event Analysis 
 The objectives of the study presented in Chapter 3 were to identify risk factors for 
gastrointestinal and intracranial bleeding among older veterans prescribed OACs, and to 
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calculate the relative risk of bleeding over time through time-to-event analysis. This study found 
that as the time from OAC prescription increased, the proportion of veterans age 50 and older 
who did not experience a gastrointestinal or intracranial bleeding event after being prescribed 
warfarin was similar to those prescribed DOACs in the first eight months after prescription, but 
those prescribed warfarin experienced slightly more bleeding from month nine through the end 
of the study period. Findings were similar but slightly more divergent among veterans with a 
diagnosis of atrial fibrillation. This finding was reversed in subjects age 75 or older at 7 through 
12 and 36 months after prescription, where the proportion of subjects who did not experience a 
bleeding event was slightly lower for those prescribed warfarin compared to those prescribed 
DOACs. These differences were small and not statistically significant. 
 This study also found that prescriptions for antidepressants (HR = 1.35, 95% CI = 1.07, 
1.70) or statins (HR = 1.31, 95% CI = 1.05, 1.63) were the strongest risk factors for 
gastrointestinal or intracranial bleeding for all subjects, while history of bleeding was the 
strongest risk factor for subjects with a diagnosis of atrial fibrillation (HR = 37.89, 95% CI = 
15.56, 92.25) and for subjects age 75 or older (HR = 21.15, 95% CI = 7.93, 56.45). 
 Both hypotheses associated with the aim of this study were disproved: 
(1) Hypothesis – variables estimating socioeconomic deprivation – Townsend 
score and median household income by Zip code – will be significant risk 
factors for gastrointestinal and intracranial bleeding. 
a. Finding – variables estimating socioeconomic deprivation were not 




(2) Hypothesis – being prescribed an OAC for a longer period of time will be 
associated with increased risk of gastrointestinal or intracranial bleeding. 
a. Finding – time-to-event estimates found no statistically significant 
difference in bleeding events as observation time in the study 
increased. 
5.2.c Chapter 4 – Predicting Bleeding Risk 
 The objectives of the study presented in Chapter 4 were to develop and compare models 
to predict gastrointestinal and intracranial bleeding among veterans age 50 to 89 who were 
prescribed warfarin or DOACs using traditional and machine learning methods. 
 Twelve models were developed and evaluated. This study found that a logistic regression 
model using the traditional ORBIT algorithm33 performed the best overall and had an AUC of 
0.75. A logistic regression model with a best subset of five variables algorithm performed second 
best, and had an AUC of 0.85. Two machine learning algorithms also performed fairly well in 
predicting bleeding risk: a lasso model with an AUC of 0.85, and a CART model with an AUC 
of 0.82. Overall model performance was based on five unweighted performance measures. This 
study compared HAS-BLED, ATRIA, ORBIT, and QBLEED to logistic regression and machine 
learning predictive models and found a model using the ORBIT score performed best, and with a 
higher AUC than that found in previously published studies. 
 Both hypotheses associated with the aim of this study were disproved: 
(1) Hypothesis – one or more algorithms produced using Machine Learning will 
accurately predict gastrointestinal and intracranial bleeding, with a sensitivity 
of 80% or greater and a positive predictive value of 75% or greater. 
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a. Finding – none of the models evaluated had a sensitivity of 80% or 
greater, and only the ORBIT model had a positive predictive value of 
75% or greater, at 78%. 
(2) Hypothesis – machine learning algorithms will perform better than the 
traditional algorithms to which they are compared (HAS-BLED, ATRIA, 
ORBIT, and QBLEED) at predicting risk of gastrointestinal and intracranial 
bleeding. 
a. Finding – a traditional algorithm (ORBIT) using logistic regression 
performed better than the machine learning algorithms to which it was 
compared. A logistic regression model with a subset of 5 variables 
performed second best. 
5.3 Limitations 
 The three studies presented in this dissertation had several limitations. The primary 
source of data used in these studies came from a VA clinical and administrative database of 
electronic health record data, and did not include non-VA claims or pharmacy benefit data, so 
services and prescriptions obtained outside the VA healthcare system were not included. 
Secondary data sources included American Community Survey and National Center for Health 
Statistics data at the Zip code- and county-level, which may not have been applicable to every 
subject in the study equally. 
 Subjects included in these studies were chosen based on outpatient utilization rather than 
on hospitalization and subsequent OAC prescription. It is possible that using a post-
hospitalization cohort would have yielded different results, or that the risks of recently 
discharged patients differ from those who have not been recently hospitalized. The subjects in 
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the study cohort were overwhelmingly male; veterans as a population have higher proportions of 
older white males with more comorbid conditions than the general population,8 so it’s uncertain 
how applicable findings from these three studies are to female veterans and to non-veterans. The 
subjects included in these studies primarily lived in New York and New Jersey, and regional 
differences in demographics may limit the generalizability of findings to other states or regions 
of the U.S. Subjects were not matched by propensity score or diagnosis-related groups across 
OAC categories, and it’s possible that this kind of matching would have had an impact on 
findings. Also, bleeding events were not categorized according to clinical significance, or 
excluded for being minor or clinically insignificant. 
 None of the studies presented here examined the relationship between gastrointestinal 
and intracranial bleeding and different OAC doses, changes in dose, or changes from one OAC 
to another. The study presented in Chapter 2 only examined the impact of two different blackout 
periods between first OAC prescription and subsequent bleeding events, and it is possible that 
other blackout periods could result in different findings. The study presented in Chapter 3 did not 
compare time-to-event between warfarin and each DOAC (dabigatran, rivaroxaban, and 
apixaban) separately, which could have identified key differences between the three DOACs 
included in the study. Also, this study included subjects with a variety of diagnoses that are 
common indications for OAC prescription. In future research it will be important to include 
comparisons of each DOAC with warfarin, and to analyze subpopulations with specific 
diagnoses, because recent studies have found differences in outcomes in both of these areas,96,98 
though these studies did not focus on veterans. 
 The study presented in Chapter 4 utilized minimal data preprocessing (such as centering, 
scaling, imputation, and resampling) and no model tuning prior to training the 12 predictive 
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models that were compared. It is possible that structuring variables in different ways – as 
categorical, changing the number of categories, binary, continuous – and the use of tuning 
techniques such as cross-validation could change the outcome of different models. This study 
split the data 50/50 for training and validation, in order to distribute the outcome evenly for 
model learning. It is possible that different data splits could change the results of the models. 
Machine learning tools perform better with larger datasets,44 and the datasets used for the study 
in Chapter 4 had 2,505 subjects each (training and validation), but machine learning algorithms 
improve with increasing amounts of data so it is possible the machine learning algorithms used 
in this study would have performed better with larger datasets. Finally, this study focused heavily 
on logistic regression and machine learning variants of logistic regression, and it is possible that 
other machine learning algorithms for classification, such as support vector machine, k-nearest 
neighbors, or discriminant analysis would have performed differently or better. 
5.4 Synthesis and Implications 
 Because the three studies presented in this dissertation were designed to build on one 
another, and two of the studies used a subset of the cohort, there were no findings that were 
applicable across all three studies. Several findings from the studies presented in this dissertation 
were consistent with previous research: 
• Subjects prescribed warfarin experienced bleeding in the first 30 days following 
prescription, while those prescribed DOACs did not. 
• Subjects prescribed warfarin experienced bleeding sooner than those prescribed DOACs, 
except in subjects age 75 or older this finding was reversed – though this finding was not 
statistically significant. 
• A prescription for antidepressants, a prescription for statins, and a history of bleeding 
were the strongest risk factors associated with gastrointestinal and intracranial bleeding. 
Other findings contradicted previous research: 
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• Incidence rates and odds of gastrointestinal and intracranial bleeding were lower in this 
study cohort than those found in previous studies. 
• Townsend score and many other variables identified as significant risk factors in other 
study populations were not significant risk factors in this cohort of older veterans. 
And some findings did not have any previous studies to which they could be compared: 
• The use of different blackout periods in determining whether to count an event as an 
outcome had a significant impact on results. 
• Veterans in the study cohort who were not prescribed OACs had gastrointestinal bleeding 
that was 9-10 times higher and intracranial bleeding that was 7-8 times higher than what 
would be expected in the general population. 
• A predictive model using a traditional algorithm (ORBIT) and logistic regression 
performed better than other traditional algorithms (HAS-BLED and ATRIA), time-to-
event (QBLEED), and machine learning models in predicting gastrointestinal and 
intracranial bleeding risk. 
 
 The studies presented in this dissertation contribute to the body of research knowledge 
about veterans and gastrointestinal and intracranial bleeding following OAC prescription. These 
studies aimed to help healthcare organizations meet the goals set forth in the National Action 
Plan for Adverse Drug Event Prevention,4 and The Joint Commission Patient Safety Goals,37 as 
well as assist VA healthcare facilities comply with the VHA Policy for Anticoagulation Therapy 
Management.40 The ORBIT algorithm,33 a set of five variables readily available in electronic 
health record data, results in a score that can be used in a logistic regression model to assign 
predicted bleeding risk to patients prescribed OACs. A simpler intervention without the use of 
predictive models could target those with a history of bleeding who are prescribed OACs, based 
on the strength of this single predictor. 
5.5 Conclusion and Recommendations for Future Research 
 The challenge of minimizing gastrointestinal and intracranial bleeding following OAC 
prescription is on-going, and while the studies presented in this dissertation shed light on some 
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areas regarding older veterans and risk of gastrointestinal and intracranial bleeding, there is still a 
need for more research. Potential future research topics include: 
• Investigation into the higher occurrence of gastrointestinal and intracranial bleeding 
among older veterans not prescribed OACs, and how much of this increase can be 
explained by a higher disease burden in veterans. 
• Research to uncover why bleeding incidence rates among older veterans prescribed 
OACs were lower than previous research in non-veterans. 
• Investigation of different machine learning algorithms to predict bleeding risk. 
 
The greatest gains in preventing ADEs will likely be realized with increased sharing and use of 
electronic health data, and the ability to discover predictive models that perform well on a variety 

















Appendix 1. List of ICD-9 and ICD-10 Codes for Gastrointestinal and Intracranial Bleeding as 
an Outcome. 
 
ICD-9 Code ICD-9 Description 
455.2 Other hemorrhoids 
455.5 Residual hemorrhoidal skin tags 
456.0 Esophageal varices with bleeding  
456.20 Secondary esophageal varices with bleeding 
530.7 Gastro-esophageal laceration-bleed syndrome  
530.82 Other specified diseases of esophagus 
531.00 Gastric ulcer - Acute with bleed  
531.10 Gastric ulcer - Acute with perforation  
531.20 Gastric ulcer - Acute with both bleed and perforation  
531.40 Gastric ulcer - Chronic or unspecified with bleed  
531.50 Gastric ulcer - Chronic or unspecified with perforation  
531.60 Gastric ulcer - Chronic or unspecified with both bleed and perforation  
532.00 Duodenal ulcer - Acute with bleed  
532.10 Duodenal ulcer - Acute with perforation  
532.20 Duodenal ulcer - Acute with both bleed and perforation  
532.40 Duodenal ulcer - Chronic or unspecified with bleed  
532.50 Duodenal ulcer - Chronic or unspecified with perforation  
532.60 Duodenal ulcer - Chronic or unspecified with both bleed and perforation  
533.00 Peptic ulcer, site unspecified - Acute with bleed  
533.10 Peptic ulcer, site unspecified - Acute with perforation  
533.20 Peptic ulcer, site unspecified - Acute with both bleed and perforation  
533.40 Peptic ulcer, site unspecified - Chronic or unspecified with bleed  
533.50 Peptic ulcer, site unspecified - Chronic or unspecified with perforation  
533.60 
Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and 
perforation  
534.00 Gastrojejunal ulcer - Acute with bleed  
534.10 Gastrojejunal ulcer - Acute with perforation  
534.20 Gastrojejunal ulcer - Acute with both bleed and perforation  
534.40 Gastrojejunal ulcer - Chronic or unspecified with bleed  
534.50 Gastrojejunal ulcer - Chronic or unspecified with perforation  
534.60 Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation  
535.01 Acute haemorrhagic gastritis  
535.11 Atrophic gastritis with hemorrhage 
535.21 Gastric mucosal hypertrophy with hemorrhage 
535.31 Alcoholic gastritis with hemorrhage 
535.41 Other specified gastritis with hemorrhage 
535.51 Unspecified gastritis and gastroduodenitis with hemorrhage 
535.61 Duodenitis with hemorrhage 
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537.83 Angiodysplasia of stomach and duodenum with hemorrhage 
562.02 Diverticulosis of small intestine with hemorrhage 
562.03 Diverticulitis of small intestine with hemorrhage 
562.12 Diverticulosis of colon with hemorrhage hemorrhage 
562.13 Diverticulitis of small intestine with hemorrhage 
568.81 Hemoperitoneum 
569.3 Hemorrhage of rectum and anus 
569.85 Angiodysplasia of intestine with hemorrhage 
569.86 Dieulafoy lesion (hemorrhagic) of intestine 
578.0 Hematemesis  
578.1 Melena  
578.9 Gastrointestinal bleed, unspecified  
430 Subarachnoid bleed  
431 Intracerebral bleed  
432 Other nontraumatic intracranial bleed  
432.1 Subdural bleed (acute)(nontraumatic)  
432.9 Intracranial bleed (nontraumatic), unspecified  
438.9 Unspecified sequelae of nontraumatic subarachnoid hemorrhage 
800.30 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with state of consciousness unspecified 
800.31 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with no loss of consciousness 
800.32 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with brief (less than 1 hour) loss of consciousness 
800.33 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with moderate (1-24 hours) loss of consciousness 
800.34 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with prolonged (more than 24 hours) loss of consciousness 
800.35 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with prolonged (more than 24 hours) loss of consciousness without returning to 
previous existing conscious level 
800.36 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with  loss of consciousness of unspecified duration 
800.39 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with concussion 
997.02 Iatrogenic cerebrovascular infarction or hemorrhage 
ICD-10 
CODE ICD-10 CODE DESCRIPTION 
I85.0  Esophageal varices with bleeding  
I85.11 Secondary esophageal varices with bleeding 
K22.6  Gastro-esophageal laceration-bleed syndrome  
K22.8 Other specified diseases of esophagus 
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K25.0  Acute gastric ulcer with hemorrhage 
K25.1  Gastric ulcer - Acute with perforation  
K25.2  Gastric ulcer - Acute with both bleed and perforation  
K25.4  Gastric ulcer - Chronic or unspecified with bleed  
K25.5  Gastric ulcer - Chronic or unspecified with perforation  
K25.6  Gastric ulcer - Chronic or unspecified with both bleed and perforation  
K26.0  Duodenal ulcer - Acute with bleed  
K26.1  Duodenal ulcer - Acute with perforation  
K26.2  Duodenal ulcer - Acute with both bleed and perforation  
K26.4  Duodenal ulcer - Chronic or unspecified with bleed  
K26.5  Duodenal ulcer - Chronic or unspecified with perforation  
K26.6  Duodenal ulcer - Chronic or unspecified with both bleed and perforation  
K27.0  Peptic ulcer, site unspecified - Acute with bleed  
K27.1  Peptic ulcer, site unspecified - Acute with perforation  
K27.2  Peptic ulcer, site unspecified - Acute with both bleed and perforation  
K27.4  Peptic ulcer, site unspecified - Chronic or unspecified with bleed  
K27.5  Peptic ulcer, site unspecified - Chronic or unspecified with perforation  
K27.6  
Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and 
perforation  
K28.0  Gastrojejunal ulcer - Acute with bleed  
K28.1  Gastrojejunal ulcer - Acute with perforation  
K28.2  Gastrojejunal ulcer - Acute with both bleed and perforation  
K28.4  Gastrojejunal ulcer - Chronic or unspecified with bleed  
K28.5  Gastrojejunal ulcer - Chronic or unspecified with perforation  
K28.6  Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation  
K29.0  Acute haemorrhagic gastritis  
K29.21 Alcoholic gastritis with hemorrhage 
K29.41 Atrophic gastritis with hemorrhage 
K29.51 Unspecified chronic gastritis with bleeding 
K29.61 Gastric mucosal hypertrophy with hemorrhage 
K29.71 Unspecified gastritis and gastroduodenitis with hemorrhage 
K29.81 Duodenitis with hemorrhage 
K29.91 Gastroduodenitis with bleeding 
K318.11 Angiodysplasia of stomach and duodenum with hemorrhage 
K55.21 Angiodysplasia of intestine with hemorrhage 
K57.11 Diverticulosis of small intestine with hemorrhage 
K57.13 Diverticulitis of small intestine with hemorrhage 
K57.31 Diverticulosis of colon with hemorrhage hemorrhage 
K57.33 Diverticulitis of small intestine with hemorrhage 
K62.5 Hemorrhage of rectum and anus 
K64.4 Residual hemorrhoidal skin tags 





Intraoperative hemorrhage and hematoma of a digestive system organ or 
structure complicating a digestive sytem procedure 
K91.62 
Intraoperative hemorrhage and hematoma of a digestive system organ or 
structure complicating other procedure 
K92.0  Hematemesis  
K92.1  Melena  
K92.2  Gastrointestinal bleed, unspecified  
K94.01 Colostomy hemorrhage 
K94.11 Enterostomy hemorrhage 
K94.21 Gastrostomy hemorrhage 
K94.31 Esophagostomy hemorrhage 
I60.00  Subarachnoid bleed from carotid siphon and bifurcation  
I60.01 
Nontraumatic subarachnoid hemorrhage from right carotid siphon and 
bifurcation 
I60.02 
Nontraumatic subarachnoid hemorrhage from left carotid siphon and 
bifurcation 
I60.10  Subarachnoid bleed from middle cerebral artery  
I60.11 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery 
I60.12 Nontraumatic subarachnoid hemorrhage from left middle cerebral artery 
I60.20  Subarachnoid bleed from anterior communicating artery  
I60.21 
Nontraumatic subarachnoid hemorrhage from right anterior communicating 
artery 
I60.22 
Nontraumatic subarachnoid hemorrhage from left anterior communicating 
artery 
I60.30  Subarachnoid bleed from posterior communicating artery  
I60.31 
Nontraumatic subarachnoid hemorrhage from right posterior communicating 
artery 
I60.32 
Nontraumatic subarachnoid hemorrhage from left posterior communicating 
artery 
I60.40  Subarachnoid bleed from basilar artery  
I60.50  Subarachnoid bleed from vertebral artery  
I60.51 Nontraumatic subarachnoid hemorrhage from right vertebral artery 
I60.52 Nontraumatic subarachnoid hemorrhage from left vertebral artery 
I60.6 Subarachnoid bleed from other intracranial arteries  
I60.7  Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery 
I60.8  Other nontraumatic subarachnoid hemorrhage 
I60.9  Nontraumatic subarachnoid hemorrhage, unspecified 
I61.0 Nontraumatic intracerebral hemorrhage in hemisphere, subcortical 
I61.1  Intracerebral bleed in hemisphere, cortical  
I61.2  Intracerebral bleed in hemisphere, unspecified  
I61.3  Intracerebral bleed in brain stem  
I61.4  Intracerebral bleed in cerebellum  
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I61.5  Intracerebral bleed, intraventricular  
I61.6  Intracerebral bleed, multiple localized  
I61.8  Other intracerebral bleed  
I61.9  Intracerebral bleed, unspecified  
I62.00 Nontraumatic subdural hemorrhage, unspecified 
I62.01 Nontraumatic acute subdural hemorrhage 
I62.02 Nontraumatic subacute subdural hemorrhage 
I62.03 Nontraumatic chronic subdural hemorrhage 
I62.1  Nontraumatic extradural hemorrhage 
I62.9  Nontraumatic intracranial hemorrhage, unspecified 
I69.00 Unspecified sequelae of nontraumatic subarachnoid hemorrhage 
I69.10 Unspecified sequelae of nontraumatic intracerebral hemorrhage 
I69.20 Unspecified sequelae of other nontraumatic intracranial hemorrhage 



































Appendix 2. List of ICD-9 and ICD-10 Codes for History of Bleeding Covariate. 
 
ICD-9 Code ICD-9 Description 
078.6 Hemorrhagic nephrosonephritis 
246.3 Hemorrhage and infarction of thyroid 
252.8 Other specified disorders of parathyroid gland 
280.0 Iron deficiency anemia secondary to blood loss (chronic) 
285.1 Acute posthemorrhagic anemia 
286.52 Acquired hemophilia 
286.59 
Other hemorrhagic disorder due to intrinsic circulating anticoagulants, 
antibodies, or inhibitors 
286.6 Defibrination syndrome 
286.9 Other and unspecified coagulation defects 
287.30 Primary thrombocytopenia, unspecified 
287.39 Other primary thrombocytopenia 
287.49 Other secondary thrombocytopenia 
287.8 Other specified hemorrhagic conditions 
287.9 Unspecified hemorrhagic conditions 
360.43 Hemophthalmos except current injury 
362.43 Hemorrhagic detach of retinal pigment epithelium 
362.81 Retinal hemorrhage 
363.61 Choroidal hemorrhage unspecified 
363.62 Expulsive choroidal hemorrhage 
363.72 Hemorrhagic choroidal detach 
364.41 Hyphema of iris and ciliary body 
372.72 Conjunctival hemorrhage 
374.81 Hemorrhage of eyelid 
376.32 Orbital hemorrhage 
377.42 Hemorrhage in optic nerve sheaths 
379.23 Vitreous hemorrhage 
423.0 Hemopericardium 
430 Subarachnoid bleed  
431 Intracerebral bleed  
432 Other nontraumatic intracranial bleed  
432.1 Subdural bleed (acute)(nontraumatic)  
432.9 Intracranial bleed (nontraumatic), unspecified  
438.9 Unspecified sequelae of nontraumatic subarachnoid hemorrhage 
455.2 Other hemorrhoids 
455.5 Residual hemorrhoidal skin tags 
456.0 Esophageal varices with bleeding  
456.20 Secondary esophageal varices with bleeding 
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459.0 Hemorrhage unspecified 
511.89 Hemothorax 
530.7 Gastro-esophageal laceration-bleed syndrome  
530.82 Other specified diseases of esophagus 
531.00 Gastric ulcer - Acute with bleed  
531.10 Gastric ulcer - Acute with perforation  
531.20 Gastric ulcer - Acute with both bleed and perforation  
531.40 Gastric ulcer - Chronic or unspecified with bleed  
531.50 Gastric ulcer - Chronic or unspecified with perforation  
531.60 Gastric ulcer - Chronic or unspecified with both bleed and perforation  
532.00 Duodenal ulcer - Acute with bleed  
532.10 Duodenal ulcer - Acute with perforation  
532.20 Duodenal ulcer - Acute with both bleed and perforation  
532.40 Duodenal ulcer - Chronic or unspecified with bleed  
532.50 Duodenal ulcer - Chronic or unspecified with perforation  
532.60 Duodenal ulcer - Chronic or unspecified with both bleed and perforation  
533.00 Peptic ulcer, site unspecified - Acute with bleed  
533.10 Peptic ulcer, site unspecified - Acute with perforation  
533.20 Peptic ulcer, site unspecified - Acute with both bleed and perforation  
533.40 Peptic ulcer, site unspecified - Chronic or unspecified with bleed  
533.50 Peptic ulcer, site unspecified - Chronic or unspecified with perforation  
533.60 
Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and 
perforation  
534.00 Gastrojejunal ulcer - Acute with bleed  
534.10 Gastrojejunal ulcer - Acute with perforation  
534.20 Gastrojejunal ulcer - Acute with both bleed and perforation  
534.40 Gastrojejunal ulcer - Chronic or unspecified with bleed  
534.50 Gastrojejunal ulcer - Chronic or unspecified with perforation  
534.60 Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation  
535.01 Acute haemorrhagic gastritis  
535.11 Atrophic gastritis with hemorrhage 
535.21 Gastric mucosal hypertrophy with hemorrhage 
535.31 Alcoholic gastritis with hemorrhage 
535.41 Other specified gastritis with hemorrhage 
535.51 Unspecified gastritis and gastroduodenitis with hemorrhage 
535.61 Duodenitis with hemorrhage 
537.83 Angiodysplasia of stomach and duodenum with hemorrhage 
562.02 Diverticulosis of small intestine with hemorrhage 
562.03 Diverticulitis of small intestine with hemorrhage 
562.12 Diverticulosis of colon with hemorrhage hemorrhage 




569.3 Hemorrhage of rectum and anus 
569.85 Angiodysplasia of intestine with hemorrhage 
569.86 Dieulafoy lesion (hemorrhagic) of intestine 
578.0 Hematemesis  
578.1 Melena  
578.9 Gastrointestinal bleed, unspecified  
596.7 Hemorrhage into bladder wall 
596.89 Other specified disorders of bladder 
599.70 Hematuria, unspecified 
599.71 Gross hematuria 
599.72 Other microscopic hematuria 
602.1 Congestion or hemorrhage of prostate 
620.1 Corpusluteum cyst or hematoma 
620.8 Other noninflammatory disorders of ovary, fallopian tube, and broad ligament 
621.4 Hematometra 
622.8 Other specified noninflammatory disorders of cervix 
623.8 Other specified noninflammatory disorders of vagina 
626.2 Excessive or frequent menstruation 
626.4 Irregular menstrual cycle 
626.5 Ovulation bleeding 
626.6 Metrorrhagia 
626.7 Postcoital bleeding 
626.8 Other disorders of menstruation and other abnormal bleeding 
626.9 Unspecified disorders of menstruation and other abnormal bleeding 
627.0 Premenopausal menorrhagia 
627.1 Postmenopausal bleeding 
719.10 Hemarthrosis site unspecified 
719.11 Herarthrosis involving shoulder region 
719.12 Herarthrosis involving upper arm 
719.13 Herarthrosis involving forearm 
719.14 Herarthrosis involving hand 
719.15 Herarthrosis involving pelvic region and thigh 
719.16 Herarthrosis involving lower leg 
719.17 Herarthrosis involving ankle and foot 
719.18 Herarthrosis involving other specified sites 
719.19 Herarthrosis involving multiple sites 
782.7 Spontaneous ecchymoses 
784.7 Epistaxis 
784.8 Hemorrhage from throat 
786.30 Hemoptysis 




Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with state of consciousness unspecified 
800.31 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with no loss of consciousness 
800.32 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with brief (less than 1 hour) loss of consciousness 
800.33 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with moderate (1-24 hours) loss of consciousness 
800.34 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with prolonged (more than 24 hours) loss of consciousness 
800.35 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with prolonged (more than 24 hours) loss of consciousness without returning to 
previous existing conscious level 
800.36 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with  loss of consciousness of unspecified duration 
800.39 
Closed fracture of vault of skull with other unspecified intracranial hemorrhage 
with concussion 
860.2 Traumatic hemothorax with open wound into thorax 
860.3 Traumatic hemothorax without open wound into thorax 
997.02 Iatrogenic cerebrovascular infarction or hemorrhage 
998.11 Hemorrhage complicating a procedure 
ICD-10 
CODE ICD-10 CODE DESCRIPTION 
D50.0 Iron deficiency anemia secondary to blood loss (chronic) 
D62 Acute posthemorrhagic anemia 
D78.01 
Intraoperative hemorrhage and hematoma of the spleen complicating a 
procedure on the spleen 
D78.02 
Intraoperative hemorrhage and hematoma of the spleen complicating other 
procedure 
E36.01 
Intraoperative hemorrhage and hematoma of an endocrine system organ or 
structure complicating an endocrine system procedure 
E36.02 
Intraoperative hemorrhage and hematoma of an endocrine system organ or 
structure complicating other procedure 
G97.31 
Intraoperative hemorrhage and hematoma of a nervous system organ or 
structure complicating a nervous system procedure 
G97.32 
Intraoperative hemorrhage and hematoma of a nervous system organ or 
structure complicating other procedure 
H05.231 Hemorrhage of right orbit 
H05.232 Hemorrhage of left orbit 
H05.233 Hemorrhage of bilateral orbit 
H05.239 Hemorrhage of unspecified orbit 
H11.30 Conjunctival hemorrhage, unspecified eye 
H11.31 Conjunctival hemorrhage, right eye 
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H11.32 Conjunctival hemorrhage, left eye 
H11.33 Conjunctival hemorrhage, bilateral 
H31.301 Unspecified choroidal hemorrhage, right eye 
H31.302 Unspecified choroidal hemorrhage, left eye 
H31.303 Unspecified choroidal hemorrhage, bilateral 
H31.309 Unspecified choroidal hemorrhage, unspecified eye 
H31.311 Expulsive choroidal hemorrhage, right eye 
H31.312 Expulsive choroidal hemorrhage, left eye 
H31.313 Expulsive choroidal hemorrhage, bilateral 
H31.319 Expulsive choroidal hemorrhage, unspecified eye 
H35.60 Retinal hemorrhage, unspecified eye 
H35.61 Retinal hemorrhage, right eye 
H35.62 Retinal hemorrhage, left eye 
H35.63 Retinal hemorrhage, bilateral 
H43.10 Vitreous hemorrhage, unspecified eye 
H43.11 Vitreous hemorrhage, right eye 
H43.12 Vitreous hemorrhage, left eye 
H43.13 Vitreous hemorrhage, bilateral 
H47.021 Hemorrhage in optic nerve sheath, right eye 
H47.022 Hemorrhage in optic nerve sheath, left eye 
H47.023 Hemorrhage in optic nerve sheath, bilateral 
H47.029 Hemorrhage in optic nerve sheath, unspecified eye 
H59.111 
Intraoperative hemorrhage and hematoma of right eye and adnexa complicating 
an ophthalmic procedure 
H59.112 
Intraoperative hemorrhage and hematoma of left eye and adnexa complicating 
an ophthalmic procedure 
H59.113 
Intraoperative hemorrhage and hematoma of eye and adnexa complicating an 
ophthalmic procedure, bilateral 
H59.119 
Intraoperative hemorrhage and hematoma of unspecified eye and adnexa 
complicating an ophthalmic procedure 
H59.121 
Intraoperative hemorrhage and hematoma of right eye and adnexa complicating 
other procedure 
H59.122 
Intraoperative hemorrhage and hematoma of left eye and adnexa complicating 
other procedure 
H59.123 
Intraoperative hemorrhage and hematoma of eye and adnexa complicating 
other procedure, bilateral 
H59.129 
Intraoperative hemorrhage and hematoma of unspecified eye and adnexa 
complicating other procedure 
H95.21 
Intraoperative hemorrhage and hematoma of ear and mastoid process 
complicating a procedure on the ear and mastoid process 
H95.22 
Intraoperative hemorrhage and hematoma of ear and mastoid process 
complicating other procedure 
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I60.00  Subarachnoid bleed from carotid siphon and bifurcation  
I60.01 
Nontraumatic subarachnoid hemorrhage from right carotid siphon and 
bifurcation 
I60.02 
Nontraumatic subarachnoid hemorrhage from left carotid siphon and 
bifurcation 
I60.10  Subarachnoid bleed from middle cerebral artery  
I60.11 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery 
I60.12 Nontraumatic subarachnoid hemorrhage from left middle cerebral artery 
I60.20  Subarachnoid bleed from anterior communicating artery  
I60.21 
Nontraumatic subarachnoid hemorrhage from right anterior communicating 
artery 
I60.22 
Nontraumatic subarachnoid hemorrhage from left anterior communicating 
artery 
I60.30  Subarachnoid bleed from posterior communicating artery  
I60.31 
Nontraumatic subarachnoid hemorrhage from right posterior communicating 
artery 
I60.32 
Nontraumatic subarachnoid hemorrhage from left posterior communicating 
artery 
I60.40  Subarachnoid bleed from basilar artery  
I60.50  Subarachnoid bleed from vertebral artery  
I60.51 Nontraumatic subarachnoid hemorrhage from right vertebral artery 
I60.52 Nontraumatic subarachnoid hemorrhage from left vertebral artery 
I60.6 Subarachnoid bleed from other intracranial arteries  
I60.7  Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery 
I60.8  Other nontraumatic subarachnoid hemorrhage 
I60.9  Nontraumatic subarachnoid hemorrhage, unspecified 
I61.0 Nontraumatic intracerebral hemorrhage in hemisphere, subcortical 
I61.1  Intracerebral bleed in hemisphere, cortical  
I61.2  Intracerebral bleed in hemisphere, unspecified  
I61.3  Intracerebral bleed in brain stem  
I61.4  Intracerebral bleed in cerebellum  
I61.5  Intracerebral bleed, intraventricular  
I61.6  Intracerebral bleed, multiple localized  
I61.8  Other intracerebral bleed  
I61.9  Intracerebral bleed, unspecified  
I62.00 Nontraumatic subdural hemorrhage, unspecified 
I62.01 Nontraumatic acute subdural hemorrhage 
I62.02 Nontraumatic subacute subdural hemorrhage 
I62.03 Nontraumatic chronic subdural hemorrhage 
I62.1  Nontraumatic extradural hemorrhage 
I62.9  Nontraumatic intracranial hemorrhage, unspecified 
I69.00 Unspecified sequelae of nontraumatic subarachnoid hemorrhage 
I69.10 Unspecified sequelae of nontraumatic intracerebral hemorrhage 
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I69.20 Unspecified sequelae of other nontraumatic intracranial hemorrhage 
I85.0  Esophageal varices with bleeding  
I85.11 Secondary esophageal varices with bleeding 
I97.410 
Intraoperative hemorrhage and hematoma of a circulatory system organ or 
structure complicating a cardiac catheterization 
I97.411 
Intraoperative hemorrhage and hematoma of a circulatory system organ or 
structure complicating a cardiac bypass 
I97.418 
Intraoperative hemorrhage and hematoma of a circulatory system organ or 
structure complicating other circulatory system procedure 
I97.42 
Intraoperative hemorrhage and hematoma of a circulatory system organ or 
structure complicating other procedure 
J94.2 Hemothorax 
J95.01 Hemorrhage from tracheostomy stoma 
J95.61 
Intraoperative hemorrhage and hematoma of a respiratory system organ or 
structure complicating a respiratory system procedure 
J95.62 
Intraoperative hemorrhage and hematoma of a respiratory system organ or 
structure complicating other procedure 
K22.6  Gastro-esophageal laceration-bleed syndrome  
K22.8 Other specified diseases of esophagus 
K25.0  Acute gastric ulcer with hemorrhage 
K25.1  Gastric ulcer - Acute with perforation  
K25.2  Gastric ulcer - Acute with both bleed and perforation  
K25.4  Gastric ulcer - Chronic or unspecified with bleed  
K25.5  Gastric ulcer - Chronic or unspecified with perforation  
K25.6  Gastric ulcer - Chronic or unspecified with both bleed and perforation  
K26.0  Duodenal ulcer - Acute with bleed  
K26.1  Duodenal ulcer - Acute with perforation  
K26.2  Duodenal ulcer - Acute with both bleed and perforation  
K26.4  Duodenal ulcer - Chronic or unspecified with bleed  
K26.5  Duodenal ulcer - Chronic or unspecified with perforation  
K26.6  Duodenal ulcer - Chronic or unspecified with both bleed and perforation  
K27.0  Peptic ulcer, site unspecified - Acute with bleed  
K27.1  Peptic ulcer, site unspecified - Acute with perforation  
K27.2  Peptic ulcer, site unspecified - Acute with both bleed and perforation  
K27.4  Peptic ulcer, site unspecified - Chronic or unspecified with bleed  
K27.5  Peptic ulcer, site unspecified - Chronic or unspecified with perforation  
K27.6  
Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and 
perforation  
K28.0  Gastrojejunal ulcer - Acute with bleed  
K28.1  Gastrojejunal ulcer - Acute with perforation  
K28.2  Gastrojejunal ulcer - Acute with both bleed and perforation  
K28.4  Gastrojejunal ulcer - Chronic or unspecified with bleed  
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K28.5  Gastrojejunal ulcer - Chronic or unspecified with perforation  
K28.6  Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation  
K29.0  Acute haemorrhagic gastritis  
K29.21 Alcoholic gastritis with hemorrhage 
K29.41 Atrophic gastritis with hemorrhage 
K29.51 Unspecified chronic gastritis with bleeding 
K29.61 Gastric mucosal hypertrophy with hemorrhage 
K29.71 Unspecified gastritis and gastroduodenitis with hemorrhage 
K29.81 Duodenitis with hemorrhage 
K29.91 Gastroduodenitis with bleeding 
K318.11 Angiodysplasia of stomach and duodenum with hemorrhage 
K55.21 Angiodysplasia of intestine with hemorrhage 
K57.11 Diverticulosis of small intestine with hemorrhage 
K57.13 Diverticulitis of small intestine with hemorrhage 
K57.31 Diverticulosis of colon with hemorrhage hemorrhage 
K57.33 Diverticulitis of small intestine with hemorrhage 
K62.5 Hemorrhage of rectum and anus 
K64.4 Residual hemorrhoidal skin tags 
K64.8 Other hemorrhoids 
K66.1 Hemoperitoneum 
K91.61 
Intraoperative hemorrhage and hematoma of a digestive system organ or 
structure complicating a digestive sytem procedure 
K91.62 
Intraoperative hemorrhage and hematoma of a digestive system organ or 
structure complicating other procedure 
K92.0  Hematemesis  
K92.1  Melena  
K92.2  Gastrointestinal bleed, unspecified  
K94.01 Colostomy hemorrhage 
K94.11 Enterostomy hemorrhage 
K94.21 Gastrostomy hemorrhage 
K94.31 Esophagostomy hemorrhage 
L76.01 
Intraoperative hemorrhage and hematoma of skin and subcutaneous tissue 
complicating a dermatologic procedure 
L76.02 
Intraoperative hemorrhage and hematoma of skin and subcutaneous tissue 
complicating other procedure 
M96.810 
Intraoperative hemorrhage and hematoma of a musculoskeletal structure 
complicating a musculoskeletal system procedure 
M96.811 
Intraoperative hemorrhage and hematoma of a musculoskeletal structure 
complicating other procedure 
N02.0 Recurrent and persistent hematuria with minor glomerular abnormality 




Recurrent and persistent hematuria with diffuse membraneous 
glomerulonephritis 
N02.3 
Recurrent and persistent hematuria with diffuse mesangial proliferative 
glomerulonephritis 
N02.4 
Recurrent and persistent hematuria with diffuse endocapillaryproliferative 
glomerulonephritis 
N02.5 
Recurrent and persistent hematuria with diffuse mesangiocapillary 
glomerulonephritis 
N02.6 Recurrent and persistent hematuria with dense deposit disease 
N02.7 Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis 
N02.8 Recurrent and persistent hematuria with other morphologic changes 
N02.9 Recurrent and persistent hematuria with unspecified morphologic changes 
N42.1 Congestion and hemorrhage of prostate 
N99.510 Cystostomy hemorrhage 
N99.520 Hemorrhage of other external stoma of urinary tract 
N99.530 Hemorrhage of other stoma of urinary tract 
N99.61 
Intraoperative hemorrhage and hematoma of a genitourinary system organ or 
structure complicating a genitourinary system procedure 
N99.62 
Intraoperative hemorrhage and hematoma of a genitourinary system organ or 
structure complicating other procedure 
R04.0 Epistaxis 
R04.1 Hemorrhage from throat 
R04.2 Hemoptysis 
R04.89 Hemorrhage from other sites in respiratory passages 
R04.9 Hemorrhage from respiratory passages, unspecified 
R31.0 Gross hematuria 
R31.1 Benign essential microscopic hematuria 
R31.2 Other microscopic hematuria 
R31.9 Hematuria, unspecified 
R58 Hemorrhage, not elsewhere classified 
S06.4X0A Epidural hemorrhage without loss of consciousness, initial encounter 
S06.4X0D Epidural hemorrhage without loss of consciousness, subsequent encounter 
S06.4X0S Epidural hemorrhage without loss of consciousness, sequela 
S06.4X1A 
Epidural hemorrhage with loss of consciousness of 30 minutes or less, initial 
encounter 
S06.4X1D 
Epidural hemorrhage with loss of consciousness of 30 minutes or less, 
subsequent encounter 
S06.4X1S Epidural hemorrhage with loss of consciousness of 30 minutes or less, sequela 
S06.4X2A 
Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, 
initial encounter 
S06.4X2D 





Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, 
sequela 
S06.4X3A 
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 
minutes, initial encounter 
S06.4X3D 
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 
minutes, subsequent encounter 
S06.4X3S 
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 
minutes, sequela 
S06.4X4A 
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial 
encounter 
S06.4X4D 
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, 
subsequent encounter 
S06.4X4S Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela 
S06.4X5A 
Epidural hemorrhage with loss of consciousness greater than 24 hours with 
return to pre-existing conscious level, initial encounter 
S06.4X5D 
Epidural hemorrhage with loss of consciousness greater than 24 hours with 
return to pre-existing conscious level, subsequent encounter 
S06.4X5S 
Epidural hemorrhage with loss of consciousness greater than 24 hours with 
return to pre-existing conscious level, sequela 
S06.4X6A 
Epidural hemorrhage with loss of consciousness greater than 24 hours without 
return to pre-existing conscious level with patient surviving, initial encounter 
S06.4X6D 
Epidural hemorrhage with loss of consciousness greater than 24 hours without 
return to pre-existing conscious level with patient surviving, subsequent 
encounter 
S06.4X6S 
Epidural hemorrhage with loss of consciousness greater than 24 hours without 
return to pre-existing conscious level with patient surviving, sequela 
S06.4X7A 
Epidural hemorrhage with loss of consciousness of any duration with death due 
to brain injury prior to regaining consciousness, initial encounter 
S06.4X7D 
Epidural hemorrhage with loss of consciousness of any duration with death due 
to brain injury prior to regaining consciousness, subsequent encounter 
S06.4X7S 
Epidural hemorrhage with loss of consciousness of any duration with death due 
to brain injury prior to regaining consciousness, sequela 
S06.4X8A 
Epidural hemorrhage with loss of consciousness of any duration with death due 
to other causes prior to regaining consciousness, initial encounter 
S06.4X8D 
Epidural hemorrhage with loss of consciousness of any duration with death due 
to other causes prior to regaining consciousness, subsequent encounter 
S06.4X8S 
Epidural hemorrhage with loss of consciousness of any duration with death due 
to other causes prior to regaining consciousness, sequela 
S06.4X9A 
Epidural hemorrhage with loss of consciousness of unspecified duration, initial 
encounter 
S06.4X9D 
Epidural hemorrhage with loss of consciousness of unspecified duration, 
subsequent encounter 
S06.4X9S 




S064-066 Traumatic intracranial hemorrhage with LOC 
T82.837A Hemorrhage of cardiac prosthetic devices, implants and grafts, initial encounter 
T82.837D 
Hemorrhage of cardiac prosthetic devices, implants and grafts, subsequent 
encounter 
T82.837S Hemorrhage of cardiac prosthetic devices, implants and grafts, sequela 
T82.838A 
Hemorrhage of vascular prosthetic devices, implants and grafts, initial 
encounter 
T82.838D 
Hemorrhage of vascular prosthetic devices, implants and grafts, subsequent 
encounter 
T82.838S Hemorrhage of vascular prosthetic devices, implants and grafts, sequela 
T83.83XA 
Hemorrhage of genitourinary prosthetic devices, implants and grafts, initial 
encounter 
T83.83XD 
Hemorrhage of genitourinary prosthetic devices, implants and grafts, 
subsequent encounter 




Appendix 3. Decision Tree Model and Gains Tables. 
 
 
Figure A.3.1. CART Machine Learning Algorithm Decision Tree Model. 
 
Key: BleedingHx = bleeding history, OACCat = warfarin prescription, months = number of 
months to bleeding outcome, medhhinc = median household income for Zip code of residence, 
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Table A.3.3. Lasso Machine Learning Model Variables and Odds Ratios. 
 
Variable Odds Ratio 
Stroke 1.10 
Bleeding History 6.10 
Months to Bleeding Event 0.97 
Warfarin 1.48 
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